Psoriasis
Conditions
Keywords
psoriasis, topical
Brief summary
This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis. The duration of study participation will be approximately 22 weeks, including up to a 6 week screening period, 12 week treatment period, and approximately 4 week follow up period. Approximately 280 participants are planned to be randomized into the study.
Interventions
DRUGPF-06700841
PF-06700841 topical cream
Vehicle topical cream
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* plaque psoriasis for 6 months * PGA score mild or moderate * body surface area (BSA) 2-15%
Exclusion criteria
* other skin conditions that would interfere with the evaluation of psoriasis * history of herpes zoster or simplex * Infected with Mycobacterium tuberculosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 | Baseline, Week 12 | The Psoriasis Area and Severity Index (PASI) score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected body surface area (BSA) from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs. |
| Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs. |
| Change From Baseline in PASI Scores at Week 14 and 16 | Baseline, Week 14 and 16 | The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs. |
| Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs. |
| Percent Change From Baseline in PASI Scores at Week 14 and 16 | Baseline, Week 14 and 16 | The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs. |
| Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch. |
| Absolute PP-NRS Score at Week 14 and 16 | Week 14 and 16 | Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch. |
| Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch. |
| Change From Baseline in PP-NRS Score at Week 14 and 16 | Baseline, Week 14 and 16 | Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch. |
| Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET (Prior to Week 12), ET Follow-up Visit 1 (2 weeks post ET) and 2 (4 weeks post ET) | PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity. |
| Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12 | Baseline, Week 12 | PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category. Scale for PGA: 0= clear, 1= almost clear, 2= mild, 3= moderate and 4= severe. Higher scores indicate more severity. |
| Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Baseline, Week 1, 2, 4, 6, 8, 10, 14, and 16 | PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category. Scale for PGA: 0= clear, 1= almost clear, 2= mild, 3= moderate and 4= severe. Higher scores indicate more severity. |
| Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity. |
| Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks) | An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and all non-SAEs. Treatment emergent AEs (TEAEs) were events that occurred between first dose of study drug and up to 4 weeks after last dose that were absent before treatment or that worsened relative to pretreatment state. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. Relatedness to study drug was assessed by the investigator. |
| Number of Participants With TEAEs by Severity | Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks) | An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. AE was assessed according to severity; mild (not causing any significant problem, dose adjustment not required), moderate (caused problem that does not interfere significantly with usual activities or the clinical status, dose adjustment needed due to adverse event) and severe (caused problem that interfered significantly with usual activities or the clinical status, study drug stopped due to adverse event). |
| Number of Participants Who Discontinued From Study Due to Adverse Events | Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks) | An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. |
| Number of Participants With Laboratory Abnormalities Meeting Specified Criteria | Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks) | Bilirubin: greater than (\>) 1.5\* upper limit normal (ULN); aspartate aminotransferase, alanine aminotransferase: \>2.5\*ULN; creatinine, cystatin C: \>1.3\*ULN; creatine kinase: \>2.0\*ULN; glomerular filtration rate (GFR) CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Equat: less than (\<) 60 milliliter (mL)/minute (min)/1.73 meter(m)\^2, greater than or equal to (\>=) 30% decrease from baseline; GFR: \<60 mL/min/1.73m\^2. |
| Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6, Post-baseline to Week 12 | Following were ECG criteria used for categorical summary:1) PR interval: percentage change \>=25/50%, QRS interval: value \>140 msec, and QT interval corrected using the Fridericia's formula (QTcF): 450 msec \< value less than equal to (\<=) 480 and 30 \< change \<=60. |
| Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Post-baseline to Week 12 | Following were the vital signs criteria: 1) Pulse rate: value \<40 beats per min (bpm), value \>120 bpm; 2) Sitting diastolic blood pressure (DBP): value \<50 mmHg; change \>=20 mmHg increase; change \>=20 mmHg decrease; 3) Sitting systolic blood pressure (SBP): value \<90 mmHg, change \>=30 mmHg increase, change \>=30 mmHg decrease; 4) Supine DBP: value \<50 mmHg, change \>=20 mmHg increase, change \>=20 mmHg decrease; 5) Supine SBP: value \<90 mmHg, change \>=30 mmHg increase, change \>=30 mmHg decrease. |
| Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | At the site of study drug application, skin tolerability was assessed for non-lesional skin surrounding the plaques on a scale from 0 to 4. Grade 0= none (no evidence of local intolerance), Grade 1= mild (minimal erythema and/or edema, slight glazed appearance), Grade 2= moderate (definite erythema and/or oedema with peeling and/or cracking but needs no adaptation of posology), Grade 3= severe, reported as AE (erythema, oedema glazing with fissures, few vesicles or papules: consider removing topical agent \[if still in place\]), Grade 4= very severe, reported as AE (strong reaction spreading beyond the treated area, bullous reaction, erosions: removal of topical agent \[if still in place\]). |
| Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET (Prior to Week 12), ET Follow-up Visit 1 (2 weeks post ET) and 2 (4 weeks post ET) | PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity. |
Countries
Australia, Bulgaria, Canada, Denmark, Germany, Hungary, Japan, Latvia, Poland, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Vehicle Once Daily (QD) During stage 1 of the study participants topically applied vehicle cream on psoriatic areas QD for a maximum of 12 weeks. Participants were followed up for 4 weeks after last dose. | 37 |
| PF-06700841 0.1% QD During stage 1 of the study participants topically applied PF-06700841 0.1% cream on psoriatic areas QD for a maximum of 12 weeks. Participants were followed up for 4 weeks after last dose. | 37 |
| PF-06700841 0.3% QD During stage 1 of the study participants topically applied PF-06700841 0.3% cream on psoriatic areas QD for a maximum of 12 weeks. Participants were followed up for 4 weeks after last dose. | 37 |
| PF-06700841 1.0% QD During stage 1 of the study participants topically applied PF-06700841 1.0% cream on psoriatic areas QD for a maximum of 12 weeks. Participants were followed up for 4 weeks after last dose. | 36 |
| PF-06700841 3.0% QD During stage 1 of the study participants topically applied PF-06700841 3.0% cream on psoriatic areas QD for a maximum of 12 weeks. Participants were followed up for 4 weeks after last dose. | 37 |
| Pooled Vehicle BID During stage 1 and 2 of the study participants topically applied vehicle cream on psoriatic areas BID for a maximum of 12 weeks. Participants were followed up for 4 weeks after last dose. | 49 |
| PF-06700841 0.3% BID During stage 1 of the study participants topically applied PF-06700841 0.3% cream on psoriatic areas BID for a maximum of 12 weeks. Participants were followed up for 4 weeks after last dose. | 36 |
| PF-06700841 1.0% BID During stage 1 of the study participants topically applied PF-06700841 1.0% cream on psoriatic areas BID for a maximum of 12 weeks. Participants were followed up for 4 weeks after last dose. | 36 |
| PF-06700841 3.0% BID During stage 2 of the study participants topically applied PF-06700841 3.0% cream on psoriatic areas BID for a maximum of 12 weeks. Participants were followed up for 4 weeks after last dose. | 38 |
| Total | 343 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Follow-up for Stage 1 | Adverse Event | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Follow-up for Stage 1 | Lack of Efficacy | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Follow-up for Stage 1 | Other | 0 | 2 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 |
| Follow-up for Stage 1 | Physician Decision | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Follow-up for Stage 1 | Refused Further Study Procedures | 0 | 1 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 |
| Follow-up for Stage 1 | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Follow-up For Stage 2 | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Follow-up For Stage 2 | Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Treatment for Stage 1 | Adverse Event | 1 | 1 | 3 | 0 | 2 | 0 | 2 | 2 | 0 | 0 |
| Treatment for Stage 1 | Death | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Treatment for Stage 1 | Lack of Efficacy | 1 | 2 | 2 | 3 | 2 | 4 | 3 | 1 | 0 | 0 |
| Treatment for Stage 1 | Lost to Follow-up | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 0 | 0 | 0 |
| Treatment for Stage 1 | No Longer Met Eligibility Criteria | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Treatment for Stage 1 | Non-Compliance With Study Drug | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treatment for Stage 1 | Other | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| Treatment for Stage 1 | Physician Decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Treatment for Stage 1 | Protocol Violation | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Treatment for Stage 1 | Randomized but not Treated | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Treatment for Stage 1 | Refused Further Treatment | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Treatment for Stage 1 | Withdrawal by Subject | 4 | 4 | 2 | 2 | 2 | 1 | 2 | 3 | 0 | 0 |
| Treatment for Stage 2 | Adverse Event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Treatment for Stage 2 | Lack of Efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Treatment for Stage 2 | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Treatment for Stage 2 | No Longer Meets Eligibility Criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Treatment for Stage 2 | Physician Decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Treatment for Stage 2 | Protocol Violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Treatment for Stage 2 | Refused Further Treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Treatment for Stage 2 | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 |
Baseline characteristics
| Characteristic | Vehicle Once Daily (QD) | PF-06700841 0.1% QD | PF-06700841 0.3% QD | PF-06700841 1.0% QD | PF-06700841 3.0% QD | Pooled Vehicle BID | PF-06700841 0.3% BID | PF-06700841 1.0% BID | PF-06700841 3.0% BID | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 48.6 Years STANDARD_DEVIATION 15.83 | 51.8 Years STANDARD_DEVIATION 12.49 | 51.4 Years STANDARD_DEVIATION 12.26 | 49.4 Years STANDARD_DEVIATION 15.3 | 48.4 Years STANDARD_DEVIATION 12.37 | 50.9 Years STANDARD_DEVIATION 12.85 | 48.2 Years STANDARD_DEVIATION 13.58 | 50.9 Years STANDARD_DEVIATION 16.45 | 48.9 Years STANDARD_DEVIATION 12.93 | 49.9 Years STANDARD_DEVIATION 13.72 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 5 Participants | 2 Participants | 4 Participants | 1 Participants | 2 Participants | 8 Participants | 3 Participants | 3 Participants | 7 Participants | 35 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 32 Participants | 35 Participants | 33 Participants | 35 Participants | 35 Participants | 39 Participants | 33 Participants | 33 Participants | 31 Participants | 306 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Asian | 6 Participants | 4 Participants | 6 Participants | 6 Participants | 4 Participants | 3 Participants | 6 Participants | 3 Participants | 2 Participants | 40 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 2 Participants | 7 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 30 Participants | 33 Participants | 28 Participants | 30 Participants | 32 Participants | 45 Participants | 30 Participants | 31 Participants | 34 Participants | 293 Participants |
| Sex: Female, Male Female | 12 Participants | 10 Participants | 7 Participants | 6 Participants | 13 Participants | 18 Participants | 11 Participants | 11 Participants | 14 Participants | 102 Participants |
| Sex: Female, Male Male | 25 Participants | 27 Participants | 30 Participants | 30 Participants | 24 Participants | 31 Participants | 25 Participants | 25 Participants | 24 Participants | 241 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 37 | 0 / 37 | 0 / 37 | 0 / 36 | 0 / 37 | 1 / 49 | 0 / 36 | 0 / 36 | 0 / 38 |
| other Total, other adverse events | 7 / 37 | 7 / 37 | 7 / 37 | 9 / 36 | 8 / 37 | 10 / 49 | 4 / 36 | 10 / 36 | 2 / 38 |
| serious Total, serious adverse events | 1 / 37 | 0 / 37 | 0 / 37 | 1 / 36 | 0 / 37 | 1 / 49 | 1 / 36 | 2 / 36 | 0 / 38 |
Outcome results
Primary
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12
The Psoriasis Area and Severity Index (PASI) score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected body surface area (BSA) from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
Time frame: Baseline, Week 12
Population: Efficacy analysis set (EAS) included all randomized participants who receive at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Vehicle Once Daily (QD) | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 | -1.6 Unit on a scale | Standard Error 0.46 |
| PF-06700841 0.1% QD | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 | -2.2 Unit on a scale | Standard Error 0.46 |
| PF-06700841 0.3% QD | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 | -1.4 Unit on a scale | Standard Error 0.46 |
| PF-06700841 1.0% QD | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 | -2.2 Unit on a scale | Standard Error 0.46 |
| PF-06700841 3.0% QD | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 | -2.4 Unit on a scale | Standard Error 0.45 |
| Pooled Vehicle BID | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 | -2.2 Unit on a scale | Standard Error 0.42 |
| PF-06700841 0.3% BID | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 | -2.5 Unit on a scale | Standard Error 0.53 |
| PF-06700841 1.0% BID | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 | -3.0 Unit on a scale | Standard Error 0.51 |
| PF-06700841 3.0% BID | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 | -2.8 Unit on a scale | Standard Error 0.48 |
p-value: 0.164190% CI: [-1.71, 0.43]ANCOVA
p-value: 0.6190% CI: [-0.89, 1.26]ANCOVA
p-value: 0.168690% CI: [-1.7, 0.45]ANCOVA
p-value: 0.105190% CI: [-1.87, 0.25]ANCOVA
p-value: 0.358390% CI: [-1.37, 0.88]ANCOVA
p-value: 0.113190% CI: [-1.88, 0.29]ANCOVA
p-value: 0.181290% CI: [-1.64, 0.47]ANCOVA
Secondary
Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12
Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10 and 12
Population: EAS included all randomized participants who receive at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure and 'number analyzed' signifies number of participants evaluable at specified time points.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Vehicle Once Daily (QD) | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 2 | 3.6 Unit on a scale | Standard Error 0.31 |
| Vehicle Once Daily (QD) | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 1 | 4.1 Unit on a scale | Standard Error 0.31 |
| Vehicle Once Daily (QD) | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Baseline | 4.6 Unit on a scale | Standard Error 0.31 |
| Vehicle Once Daily (QD) | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 4 | 3.5 Unit on a scale | Standard Error 0.32 |
| Vehicle Once Daily (QD) | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 6 | 3.5 Unit on a scale | Standard Error 0.32 |
| Vehicle Once Daily (QD) | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 8 | 3.1 Unit on a scale | Standard Error 0.32 |
| Vehicle Once Daily (QD) | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 10 | 3.3 Unit on a scale | Standard Error 0.33 |
| Vehicle Once Daily (QD) | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 12 | 3.4 Unit on a scale | Standard Error 0.33 |
| PF-06700841 0.1% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 4 | 3.7 Unit on a scale | Standard Error 0.32 |
| PF-06700841 0.1% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 1 | 3.9 Unit on a scale | Standard Error 0.3 |
| PF-06700841 0.1% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 10 | 3.0 Unit on a scale | Standard Error 0.33 |
| PF-06700841 0.1% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 2 | 3.5 Unit on a scale | Standard Error 0.31 |
| PF-06700841 0.1% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 8 | 3.4 Unit on a scale | Standard Error 0.32 |
| PF-06700841 0.1% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Baseline | 4.4 Unit on a scale | Standard Error 0.3 |
| PF-06700841 0.1% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 12 | 3.1 Unit on a scale | Standard Error 0.33 |
| PF-06700841 0.1% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 6 | 4.0 Unit on a scale | Standard Error 0.32 |
| PF-06700841 0.3% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 12 | 3.1 Unit on a scale | Standard Error 0.33 |
| PF-06700841 0.3% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 4 | 3.2 Unit on a scale | Standard Error 0.33 |
| PF-06700841 0.3% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 8 | 3.2 Unit on a scale | Standard Error 0.33 |
| PF-06700841 0.3% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 1 | 3.6 Unit on a scale | Standard Error 0.31 |
| PF-06700841 0.3% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 10 | 3.0 Unit on a scale | Standard Error 0.34 |
| PF-06700841 0.3% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 2 | 3.3 Unit on a scale | Standard Error 0.31 |
| PF-06700841 0.3% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Baseline | 4.5 Unit on a scale | Standard Error 0.31 |
| PF-06700841 0.3% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 6 | 3.5 Unit on a scale | Standard Error 0.34 |
| PF-06700841 1.0% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 1 | 3.5 Unit on a scale | Standard Error 0.33 |
| PF-06700841 1.0% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 10 | 3.1 Unit on a scale | Standard Error 0.35 |
| PF-06700841 1.0% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 12 | 3.0 Unit on a scale | Standard Error 0.35 |
| PF-06700841 1.0% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 2 | 3.2 Unit on a scale | Standard Error 0.33 |
| PF-06700841 1.0% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 4 | 3.2 Unit on a scale | Standard Error 0.34 |
| PF-06700841 1.0% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 6 | 3.2 Unit on a scale | Standard Error 0.34 |
| PF-06700841 1.0% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Baseline | 4.1 Unit on a scale | Standard Error 0.33 |
| PF-06700841 1.0% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 8 | 3.1 Unit on a scale | Standard Error 0.34 |
| PF-06700841 3.0% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 6 | 2.9 Unit on a scale | Standard Error 0.32 |
| PF-06700841 3.0% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 4 | 3.2 Unit on a scale | Standard Error 0.3 |
| PF-06700841 3.0% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 12 | 2.6 Unit on a scale | Standard Error 0.32 |
| PF-06700841 3.0% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 8 | 2.8 Unit on a scale | Standard Error 0.32 |
| PF-06700841 3.0% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 1 | 3.6 Unit on a scale | Standard Error 0.3 |
| PF-06700841 3.0% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 10 | 2.3 Unit on a scale | Standard Error 0.32 |
| PF-06700841 3.0% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 2 | 3.5 Unit on a scale | Standard Error 0.3 |
| PF-06700841 3.0% QD | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Baseline | 4.5 Unit on a scale | Standard Error 0.29 |
| Pooled Vehicle BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 1 | 4.0 Unit on a scale | Standard Error 0.28 |
| Pooled Vehicle BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 12 | 4.0 Unit on a scale | Standard Error 0.32 |
| Pooled Vehicle BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 2 | 3.5 Unit on a scale | Standard Error 0.28 |
| Pooled Vehicle BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 10 | 4.1 Unit on a scale | Standard Error 0.33 |
| Pooled Vehicle BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 6 | 3.6 Unit on a scale | Standard Error 0.31 |
| Pooled Vehicle BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 4 | 3.4 Unit on a scale | Standard Error 0.29 |
| Pooled Vehicle BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 8 | 3.3 Unit on a scale | Standard Error 0.32 |
| Pooled Vehicle BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Baseline | 4.9 Unit on a scale | Standard Error 0.28 |
| PF-06700841 0.3% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 12 | 2.7 Unit on a scale | Standard Error 0.37 |
| PF-06700841 0.3% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Baseline | 4.8 Unit on a scale | Standard Error 0.32 |
| PF-06700841 0.3% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 2 | 3.6 Unit on a scale | Standard Error 0.32 |
| PF-06700841 0.3% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 8 | 2.7 Unit on a scale | Standard Error 0.37 |
| PF-06700841 0.3% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 6 | 2.8 Unit on a scale | Standard Error 0.35 |
| PF-06700841 0.3% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 4 | 3.0 Unit on a scale | Standard Error 0.34 |
| PF-06700841 0.3% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 1 | 3.8 Unit on a scale | Standard Error 0.32 |
| PF-06700841 0.3% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 10 | 2.8 Unit on a scale | Standard Error 0.36 |
| PF-06700841 1.0% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Baseline | 4.4 Unit on a scale | Standard Error 0.32 |
| PF-06700841 1.0% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 1 | 3.4 Unit on a scale | Standard Error 0.32 |
| PF-06700841 1.0% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 2 | 2.9 Unit on a scale | Standard Error 0.32 |
| PF-06700841 1.0% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 4 | 3.0 Unit on a scale | Standard Error 0.34 |
| PF-06700841 1.0% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 6 | 3.0 Unit on a scale | Standard Error 0.35 |
| PF-06700841 1.0% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 8 | 2.9 Unit on a scale | Standard Error 0.35 |
| PF-06700841 1.0% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 12 | 3.0 Unit on a scale | Standard Error 0.35 |
| PF-06700841 1.0% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 10 | 2.9 Unit on a scale | Standard Error 0.35 |
| PF-06700841 3.0% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 12 | 3.2 Unit on a scale | Standard Error 0.4 |
| PF-06700841 3.0% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 10 | 3.6 Unit on a scale | Standard Error 0.39 |
| PF-06700841 3.0% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 8 | 2.7 Unit on a scale | Standard Error 0.38 |
| PF-06700841 3.0% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 6 | 2.9 Unit on a scale | Standard Error 0.38 |
| PF-06700841 3.0% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 4 | 3.4 Unit on a scale | Standard Error 0.36 |
| PF-06700841 3.0% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 2 | 3.4 Unit on a scale | Standard Error 0.35 |
| PF-06700841 3.0% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Week 1 | 3.7 Unit on a scale | Standard Error 0.35 |
| PF-06700841 3.0% BID | Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 | Baseline | 5.4 Unit on a scale | Standard Error 0.34 |
Comparison: Baseline: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.327990% CI: [-0.91, 0.52]MMRM
Comparison: Baseline: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.356690% CI: [-0.88, 0.56]MMRM
Comparison: Baseline: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.116590% CI: [-1.29, 0.21]MMRM
Comparison: Baseline: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.363390% CI: [-0.85, 0.55]MMRM
Comparison: Baseline: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.376690% CI: [-0.83, 0.56]MMRM
Comparison: Baseline: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.117990% CI: [-1.22, 0.2]MMRM
Comparison: Baseline: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.864790% CI: [-0.24, 1.2]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.329490% CI: [-0.9, 0.52]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.123190% CI: [-1.23, 0.21]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.087890% CI: [-1.37, 0.13]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.122590% CI: [-1.2, 0.21]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.366390% CI: [-0.85, 0.56]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.092990% CI: [-1.27, 0.14]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.311190% CI: [-0.95, 0.51]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.474590% CI: [-0.74, 0.69]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.240990% CI: [-1.03, 0.42]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.201890% CI: [-1.13, 0.37]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.392590% CI: [-0.83, 0.59]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.534890% CI: [-0.66, 0.73]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.073990% CI: [-1.33, 0.09]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.401490% CI: [-0.84, 0.62]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.658890% CI: [-0.56, 0.93]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.299790% CI: [-1, 0.52]MMRM
Comparison: Week 4:MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.251890% CI: [-1.08, 0.46]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.263490% CI: [-1, 0.45]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.199990% CI: [-1.11, 0.36]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.184790% CI: [-1.13, 0.33]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.456990% CI: [-0.81, 0.71]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.853690% CI: [-0.27, 1.22]MMRM
Comparison: Week 6:MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.481290% CI: [-0.79, 0.74]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.227690% CI: [-1.13, 0.42]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.089590% CI: [-1.34, 0.14]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.041190% CI: [-1.58, -0.04]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.092890% CI: [-1.4, 0.15]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.079990% CI: [-1.48, 0.12]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.787290% CI: [-0.39, 1.11]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.629490% CI: [-0.61, 0.92]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.517490% CI: [-0.76, 0.8]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.313690% CI: [-0.98, 0.53]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.10290% CI: [-1.42, 0.18]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.192390% CI: [-1.2, 0.37]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.099790% CI: [-1.44, 0.18]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.249790% CI: [-1.08, 0.45]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.256890% CI: [-1.08, 0.47]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.37390% CI: [-0.95, 0.64]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.013790% CI: [-1.76, -0.26]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.005590% CI: [-2.06, -0.44]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.006990% CI: [-1.99, -0.4]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.164890% CI: [-1.34, 0.34]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.293190% CI: [-1.02, 0.51]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.304790% CI: [-1.01, 0.53]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.192490% CI: [-1.22, 0.38]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.046590% CI: [-1.52, -0.02]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.004890% CI: [-2.08, -0.47]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.018690% CI: [-1.78, -0.21]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Compound symmetry covariance matrix was used for model errors.p-value: 0.067590% CI: [-1.61, 0.08]MMRM
Secondary
Absolute PP-NRS Score at Week 14 and 16
Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.
Time frame: Week 14 and 16
Population: EAS included all randomized participants who receive at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure and 'number analyzed' signifies number of participants evaluable at specified time points.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Vehicle Once Daily (QD) | Absolute PP-NRS Score at Week 14 and 16 | Week 14 | 5.2 Unit on a scale | Standard Deviation 3.02 |
| Vehicle Once Daily (QD) | Absolute PP-NRS Score at Week 14 and 16 | Week 16 | 4.9 Unit on a scale | Standard Deviation 2.93 |
| PF-06700841 0.1% QD | Absolute PP-NRS Score at Week 14 and 16 | Week 14 | 2.6 Unit on a scale | Standard Deviation 2.52 |
| PF-06700841 0.1% QD | Absolute PP-NRS Score at Week 14 and 16 | Week 16 | 3.2 Unit on a scale | Standard Deviation 2.75 |
| PF-06700841 0.3% QD | Absolute PP-NRS Score at Week 14 and 16 | Week 14 | 2.8 Unit on a scale | Standard Deviation 2.38 |
| PF-06700841 0.3% QD | Absolute PP-NRS Score at Week 14 and 16 | Week 16 | 3.1 Unit on a scale | Standard Deviation 2.63 |
| PF-06700841 1.0% QD | Absolute PP-NRS Score at Week 14 and 16 | Week 14 | 2.4 Unit on a scale | Standard Deviation 2.39 |
| PF-06700841 1.0% QD | Absolute PP-NRS Score at Week 14 and 16 | Week 16 | 2.5 Unit on a scale | Standard Deviation 2.45 |
| PF-06700841 3.0% QD | Absolute PP-NRS Score at Week 14 and 16 | Week 14 | 3.2 Unit on a scale | Standard Deviation 2.38 |
| PF-06700841 3.0% QD | Absolute PP-NRS Score at Week 14 and 16 | Week 16 | 3.2 Unit on a scale | Standard Deviation 2.42 |
| Pooled Vehicle BID | Absolute PP-NRS Score at Week 14 and 16 | Week 16 | 3.8 Unit on a scale | Standard Deviation 2.69 |
| Pooled Vehicle BID | Absolute PP-NRS Score at Week 14 and 16 | Week 14 | 4.0 Unit on a scale | Standard Deviation 2.77 |
| PF-06700841 0.3% BID | Absolute PP-NRS Score at Week 14 and 16 | Week 16 | 3.4 Unit on a scale | Standard Deviation 2.77 |
| PF-06700841 0.3% BID | Absolute PP-NRS Score at Week 14 and 16 | Week 14 | 3.5 Unit on a scale | Standard Deviation 2.89 |
| PF-06700841 1.0% BID | Absolute PP-NRS Score at Week 14 and 16 | Week 14 | 2.8 Unit on a scale | Standard Deviation 2.57 |
| PF-06700841 1.0% BID | Absolute PP-NRS Score at Week 14 and 16 | Week 16 | 3.5 Unit on a scale | Standard Deviation 2.91 |
| PF-06700841 3.0% BID | Absolute PP-NRS Score at Week 14 and 16 | Week 14 | 5.5 Unit on a scale | Standard Deviation 2.81 |
| PF-06700841 3.0% BID | Absolute PP-NRS Score at Week 14 and 16 | Week 16 | 5.8 Unit on a scale | Standard Deviation 2.76 |
Secondary
Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2
PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET (Prior to Week 12), ET Follow-up Visit 1 (2 weeks post ET) and 2 (4 weeks post ET)
Population: EAS included all randomized participants who receive at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure and 'number analyzed' signifies number of participants evaluable at specified time points.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Vehicle Once Daily (QD) | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 2 | 8.0 Unit on a scale | Standard Deviation 5.66 |
| Vehicle Once Daily (QD) | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 8 | 11.3 Unit on a scale | Standard Deviation 5.82 |
| Vehicle Once Daily (QD) | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 12 | 11.7 Unit on a scale | Standard Deviation 7.4 |
| Vehicle Once Daily (QD) | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 6 | 11.6 Unit on a scale | Standard Deviation 6.61 |
| Vehicle Once Daily (QD) | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 1 | 7.0 Unit on a scale | Standard Deviation 4.24 |
| Vehicle Once Daily (QD) | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 2 | 10.3 Unit on a scale | Standard Deviation 4.57 |
| Vehicle Once Daily (QD) | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 1 | 11.2 Unit on a scale | Standard Deviation 4.17 |
| Vehicle Once Daily (QD) | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 4 | 11.6 Unit on a scale | Standard Deviation 5.81 |
| Vehicle Once Daily (QD) | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 14 | 14.3 Unit on a scale | Standard Deviation 8.09 |
| Vehicle Once Daily (QD) | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 10 | 11.7 Unit on a scale | Standard Deviation 7.09 |
| Vehicle Once Daily (QD) | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 16 | 14.0 Unit on a scale | Standard Deviation 7.6 |
| Vehicle Once Daily (QD) | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Baseline | 14.2 Unit on a scale | Standard Deviation 5.96 |
| Vehicle Once Daily (QD) | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET | 7.7 Unit on a scale | Standard Deviation 4.04 |
| PF-06700841 0.1% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET | 13.0 Unit on a scale | Standard Deviation 1 |
| PF-06700841 0.1% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 4 | 9.2 Unit on a scale | Standard Deviation 5.25 |
| PF-06700841 0.1% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 2 | 7.0 Unit on a scale | — |
| PF-06700841 0.1% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Baseline | 12.3 Unit on a scale | Standard Deviation 7.18 |
| PF-06700841 0.1% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 16 | 8.6 Unit on a scale | Standard Deviation 6.3 |
| PF-06700841 0.1% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 1 | 9.1 Unit on a scale | Standard Deviation 5.85 |
| PF-06700841 0.1% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 8 | 8.7 Unit on a scale | Standard Deviation 5.87 |
| PF-06700841 0.1% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 10 | 8.0 Unit on a scale | Standard Deviation 6.29 |
| PF-06700841 0.1% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 1 | 9.0 Unit on a scale | — |
| PF-06700841 0.1% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 2 | 8.4 Unit on a scale | Standard Deviation 5.07 |
| PF-06700841 0.1% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 12 | 7.8 Unit on a scale | Standard Deviation 6.41 |
| PF-06700841 0.1% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 14 | 8.1 Unit on a scale | Standard Deviation 6.37 |
| PF-06700841 0.1% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 6 | 9.7 Unit on a scale | Standard Deviation 5.79 |
| PF-06700841 0.3% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 12 | 9.7 Unit on a scale | Standard Deviation 6.45 |
| PF-06700841 0.3% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 10 | 9.5 Unit on a scale | Standard Deviation 5.89 |
| PF-06700841 0.3% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 1 | 9.7 Unit on a scale | Standard Deviation 5.29 |
| PF-06700841 0.3% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Baseline | 13.2 Unit on a scale | Standard Deviation 6.55 |
| PF-06700841 0.3% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 1 | 6.0 Unit on a scale | Standard Deviation 4.24 |
| PF-06700841 0.3% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 2 | 9.2 Unit on a scale | Standard Deviation 5.03 |
| PF-06700841 0.3% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET | 12.8 Unit on a scale | Standard Deviation 6.76 |
| PF-06700841 0.3% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 4 | 9.9 Unit on a scale | Standard Deviation 5.29 |
| PF-06700841 0.3% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 16 | 9.8 Unit on a scale | Standard Deviation 5.47 |
| PF-06700841 0.3% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 6 | 10.4 Unit on a scale | Standard Deviation 6.2 |
| PF-06700841 0.3% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 14 | 8.9 Unit on a scale | Standard Deviation 6.09 |
| PF-06700841 0.3% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 8 | 9.7 Unit on a scale | Standard Deviation 6.62 |
| PF-06700841 0.3% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 2 | 4.5 Unit on a scale | Standard Deviation 2.12 |
| PF-06700841 1.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 6 | 6.2 Unit on a scale | Standard Deviation 3.79 |
| PF-06700841 1.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 2 | 4.0 Unit on a scale | — |
| PF-06700841 1.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 14 | 6.8 Unit on a scale | Standard Deviation 5 |
| PF-06700841 1.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 10 | 6.5 Unit on a scale | Standard Deviation 3.66 |
| PF-06700841 1.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Baseline | 10.3 Unit on a scale | Standard Deviation 5 |
| PF-06700841 1.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 2 | 7.1 Unit on a scale | Standard Deviation 4.01 |
| PF-06700841 1.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 1 | 4.0 Unit on a scale | — |
| PF-06700841 1.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 1 | 7.8 Unit on a scale | Standard Deviation 4.23 |
| PF-06700841 1.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 12 | 5.9 Unit on a scale | Standard Deviation 3.38 |
| PF-06700841 1.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 16 | 7.4 Unit on a scale | Standard Deviation 5.03 |
| PF-06700841 1.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 4 | 7.3 Unit on a scale | Standard Deviation 3.97 |
| PF-06700841 1.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET | 13.3 Unit on a scale | Standard Deviation 7.02 |
| PF-06700841 1.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 8 | 6.1 Unit on a scale | Standard Deviation 3.73 |
| PF-06700841 3.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 10 | 6.4 Unit on a scale | Standard Deviation 4.87 |
| PF-06700841 3.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Baseline | 12.3 Unit on a scale | Standard Deviation 6.48 |
| PF-06700841 3.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 1 | 8.9 Unit on a scale | Standard Deviation 6.1 |
| PF-06700841 3.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 2 | 8.2 Unit on a scale | Standard Deviation 5.17 |
| PF-06700841 3.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 4 | 8.1 Unit on a scale | Standard Deviation 4.89 |
| PF-06700841 3.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 6 | 7.6 Unit on a scale | Standard Deviation 4.69 |
| PF-06700841 3.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 8 | 7.0 Unit on a scale | Standard Deviation 4.61 |
| PF-06700841 3.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 12 | 6.2 Unit on a scale | Standard Deviation 4.69 |
| PF-06700841 3.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 14 | 9.2 Unit on a scale | Standard Deviation 6.12 |
| PF-06700841 3.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 16 | 8.9 Unit on a scale | Standard Deviation 6.77 |
| PF-06700841 3.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET | 15.8 Unit on a scale | Standard Deviation 11.73 |
| PF-06700841 3.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 1 | 2.0 Unit on a scale | — |
| PF-06700841 3.0% QD | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 2 | 22.5 Unit on a scale | Standard Deviation 9.19 |
| Pooled Vehicle BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 12 | 8.0 Unit on a scale | Standard Deviation 5.13 |
| Pooled Vehicle BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 16 | 10.4 Unit on a scale | Standard Deviation 6.18 |
| Pooled Vehicle BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 2 | 17.8 Unit on a scale | Standard Deviation 11.41 |
| Pooled Vehicle BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 4 | 9.6 Unit on a scale | Standard Deviation 6.96 |
| Pooled Vehicle BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 8 | 8.4 Unit on a scale | Standard Deviation 5.46 |
| Pooled Vehicle BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 10 | 7.8 Unit on a scale | Standard Deviation 4.92 |
| Pooled Vehicle BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 1 | 19.0 Unit on a scale | Standard Deviation 15.56 |
| Pooled Vehicle BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 1 | 9.6 Unit on a scale | Standard Deviation 4.86 |
| Pooled Vehicle BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET | 18.7 Unit on a scale | Standard Deviation 10.23 |
| Pooled Vehicle BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Baseline | 14.0 Unit on a scale | Standard Deviation 6.6 |
| Pooled Vehicle BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 6 | 8.8 Unit on a scale | Standard Deviation 5.96 |
| Pooled Vehicle BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 2 | 8.4 Unit on a scale | Standard Deviation 4.52 |
| Pooled Vehicle BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 14 | 10.4 Unit on a scale | Standard Deviation 5.98 |
| PF-06700841 0.3% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 8 | 7.2 Unit on a scale | Standard Deviation 4.75 |
| PF-06700841 0.3% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 12 | 6.1 Unit on a scale | Standard Deviation 3.67 |
| PF-06700841 0.3% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 6 | 6.1 Unit on a scale | Standard Deviation 3.23 |
| PF-06700841 0.3% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 14 | 11.2 Unit on a scale | Standard Deviation 7.54 |
| PF-06700841 0.3% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 4 | 7.9 Unit on a scale | Standard Deviation 5.57 |
| PF-06700841 0.3% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 16 | 11.5 Unit on a scale | Standard Deviation 7.2 |
| PF-06700841 0.3% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 2 | 9.1 Unit on a scale | Standard Deviation 5.47 |
| PF-06700841 0.3% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 2 | 4.0 Unit on a scale | Standard Deviation 0 |
| PF-06700841 0.3% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET | 18.0 Unit on a scale | Standard Deviation 11.87 |
| PF-06700841 0.3% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 1 | 9.5 Unit on a scale | Standard Deviation 4.86 |
| PF-06700841 0.3% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 1 | 8.5 Unit on a scale | Standard Deviation 2.12 |
| PF-06700841 0.3% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Baseline | 13.0 Unit on a scale | Standard Deviation 6.09 |
| PF-06700841 0.3% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 10 | 6.7 Unit on a scale | Standard Deviation 3.13 |
| PF-06700841 1.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET | 11.0 Unit on a scale | Standard Deviation 8.21 |
| PF-06700841 1.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 12 | 6.8 Unit on a scale | Standard Deviation 5.14 |
| PF-06700841 1.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 1 | 4.0 Unit on a scale | — |
| PF-06700841 1.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 6 | 6.9 Unit on a scale | Standard Deviation 5.06 |
| PF-06700841 1.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 4 | 6.6 Unit on a scale | Standard Deviation 4.6 |
| PF-06700841 1.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 1 | 7.0 Unit on a scale | Standard Deviation 4.96 |
| PF-06700841 1.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 10 | 6.7 Unit on a scale | Standard Deviation 4.6 |
| PF-06700841 1.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 8 | 7.5 Unit on a scale | Standard Deviation 4.92 |
| PF-06700841 1.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 14 | 8.5 Unit on a scale | Standard Deviation 6.04 |
| PF-06700841 1.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Baseline | 10.1 Unit on a scale | Standard Deviation 5.7 |
| PF-06700841 1.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 16 | 10.2 Unit on a scale | Standard Deviation 6.82 |
| PF-06700841 1.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 2 | 13.0 Unit on a scale | Standard Deviation 13.74 |
| PF-06700841 1.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 2 | 6.0 Unit on a scale | Standard Deviation 4.3 |
| PF-06700841 3.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 2 | 8.4 Unit on a scale | Standard Deviation 3.62 |
| PF-06700841 3.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 8 | 8.0 Unit on a scale | Standard Deviation 4.68 |
| PF-06700841 3.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 2 | 15.5 Unit on a scale | Standard Deviation 10.61 |
| PF-06700841 3.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET | 19.3 Unit on a scale | Standard Deviation 8.14 |
| PF-06700841 3.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 1 | 9.7 Unit on a scale | Standard Deviation 4.24 |
| PF-06700841 3.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 6 | 8.2 Unit on a scale | Standard Deviation 4.23 |
| PF-06700841 3.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 12 | 8.3 Unit on a scale | Standard Deviation 4.79 |
| PF-06700841 3.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 10 | 9.5 Unit on a scale | Standard Deviation 4.97 |
| PF-06700841 3.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | ET follow-up visit 1 | 7.0 Unit on a scale | — |
| PF-06700841 3.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Baseline | 16.6 Unit on a scale | Standard Deviation 7.01 |
| PF-06700841 3.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 4 | 8.3 Unit on a scale | Standard Deviation 3.99 |
| PF-06700841 3.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 14 | 11.5 Unit on a scale | Standard Deviation 5.26 |
| PF-06700841 3.0% BID | Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 | Week 16 | 11.9 Unit on a scale | Standard Deviation 7.33 |
Secondary
Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12
The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10 and 12
Population: EAS included all randomized participants who receive at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure and 'number analyzed' signifies number of participants evaluable at specified time points.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Vehicle Once Daily (QD) | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -1.4 Unit on a scale | Standard Error 0.49 |
| Vehicle Once Daily (QD) | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -1.5 Unit on a scale | Standard Error 0.35 |
| Vehicle Once Daily (QD) | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -1.6 Unit on a scale | Standard Error 0.41 |
| Vehicle Once Daily (QD) | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -1.6 Unit on a scale | Standard Error 0.39 |
| Vehicle Once Daily (QD) | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -1.4 Unit on a scale | Standard Error 0.31 |
| Vehicle Once Daily (QD) | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -0.9 Unit on a scale | Standard Error 0.22 |
| Vehicle Once Daily (QD) | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -1.4 Unit on a scale | Standard Error 0.26 |
| PF-06700841 0.1% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -0.7 Unit on a scale | Standard Error 0.22 |
| PF-06700841 0.1% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -2.1 Unit on a scale | Standard Error 0.48 |
| PF-06700841 0.1% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -0.7 Unit on a scale | Standard Error 0.26 |
| PF-06700841 0.1% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -1.4 Unit on a scale | Standard Error 0.35 |
| PF-06700841 0.1% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -2.1 Unit on a scale | Standard Error 0.4 |
| PF-06700841 0.1% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -1.2 Unit on a scale | Standard Error 0.31 |
| PF-06700841 0.1% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -1.9 Unit on a scale | Standard Error 0.39 |
| PF-06700841 0.3% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -0.9 Unit on a scale | Standard Error 0.41 |
| PF-06700841 0.3% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -0.6 Unit on a scale | Standard Error 0.22 |
| PF-06700841 0.3% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -1.2 Unit on a scale | Standard Error 0.51 |
| PF-06700841 0.3% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -1.6 Unit on a scale | Standard Error 0.42 |
| PF-06700841 0.3% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -1.2 Unit on a scale | Standard Error 0.37 |
| PF-06700841 0.3% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -0.9 Unit on a scale | Standard Error 0.27 |
| PF-06700841 0.3% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -1.2 Unit on a scale | Standard Error 0.33 |
| PF-06700841 1.0% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -1.4 Unit on a scale | Standard Error 0.26 |
| PF-06700841 1.0% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -2.3 Unit on a scale | Standard Error 0.4 |
| PF-06700841 1.0% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -0.9 Unit on a scale | Standard Error 0.22 |
| PF-06700841 1.0% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -1.4 Unit on a scale | Standard Error 0.31 |
| PF-06700841 1.0% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -2.2 Unit on a scale | Standard Error 0.48 |
| PF-06700841 1.0% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -1.6 Unit on a scale | Standard Error 0.35 |
| PF-06700841 1.0% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -2.1 Unit on a scale | Standard Error 0.39 |
| PF-06700841 3.0% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -2.4 Unit on a scale | Standard Error 0.36 |
| PF-06700841 3.0% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -0.8 Unit on a scale | Standard Error 0.22 |
| PF-06700841 3.0% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -1.3 Unit on a scale | Standard Error 0.26 |
| PF-06700841 3.0% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -1.6 Unit on a scale | Standard Error 0.31 |
| PF-06700841 3.0% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -2.3 Unit on a scale | Standard Error 0.4 |
| PF-06700841 3.0% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -2.4 Unit on a scale | Standard Error 0.41 |
| PF-06700841 3.0% QD | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -2.4 Unit on a scale | Standard Error 0.49 |
| Pooled Vehicle BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -0.5 Unit on a scale | Standard Error 0.19 |
| Pooled Vehicle BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -1.1 Unit on a scale | Standard Error 0.46 |
| Pooled Vehicle BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -1.2 Unit on a scale | Standard Error 0.37 |
| Pooled Vehicle BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -1.0 Unit on a scale | Standard Error 0.35 |
| Pooled Vehicle BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -0.9 Unit on a scale | Standard Error 0.51 |
| Pooled Vehicle BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -1.3 Unit on a scale | Standard Error 0.42 |
| Pooled Vehicle BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -0.8 Unit on a scale | Standard Error 0.25 |
| PF-06700841 0.3% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -2.4 Unit on a scale | Standard Error 0.5 |
| PF-06700841 0.3% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -2.4 Unit on a scale | Standard Error 0.55 |
| PF-06700841 0.3% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -2.5 Unit on a scale | Standard Error 0.62 |
| PF-06700841 0.3% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -0.7 Unit on a scale | Standard Error 0.23 |
| PF-06700841 0.3% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -2.3 Unit on a scale | Standard Error 0.42 |
| PF-06700841 0.3% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -2.5 Unit on a scale | Standard Error 0.45 |
| PF-06700841 0.3% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -1.4 Unit on a scale | Standard Error 0.29 |
| PF-06700841 1.0% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -2.1 Unit on a scale | Standard Error 0.44 |
| PF-06700841 1.0% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -1.6 Unit on a scale | Standard Error 0.29 |
| PF-06700841 1.0% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -1.7 Unit on a scale | Standard Error 0.41 |
| PF-06700841 1.0% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -2.3 Unit on a scale | Standard Error 0.48 |
| PF-06700841 1.0% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -2.5 Unit on a scale | Standard Error 0.59 |
| PF-06700841 1.0% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -2.4 Unit on a scale | Standard Error 0.53 |
| PF-06700841 1.0% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -0.7 Unit on a scale | Standard Error 0.22 |
| PF-06700841 3.0% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -0.8 Unit on a scale | Standard Error 0.22 |
| PF-06700841 3.0% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -2.4 Unit on a scale | Standard Error 0.53 |
| PF-06700841 3.0% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -2.3 Unit on a scale | Standard Error 0.59 |
| PF-06700841 3.0% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -1.7 Unit on a scale | Standard Error 0.29 |
| PF-06700841 3.0% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -2.5 Unit on a scale | Standard Error 0.48 |
| PF-06700841 3.0% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -2.2 Unit on a scale | Standard Error 0.41 |
| PF-06700841 3.0% BID | Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -2.1 Unit on a scale | Standard Error 0.43 |
Comparison: Week 1: Mixed-effect model with repeated measures (MMRM) analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.803890% CI: [-0.25, 0.79]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.826790% CI: [-0.22, 0.81]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.603990% CI: [-0.43, 0.6]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.633990% CI: [-0.41, 0.62]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.266690% CI: [-0.68, 0.31]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.225790% CI: [-0.7, 0.26]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.130690% CI: [-0.81, 0.15]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.970490% CI: [0.09, 1.31]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.88990% CI: [-0.16, 1.09]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.450690% CI: [-0.66, 0.57]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.58490% CI: [-0.53, 0.69]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.076990% CI: [-1.17, 0.08]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.024290% CI: [-1.39, -0.13]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.012790% CI: [-1.49, -0.23]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.669390% CI: [-0.54, 0.93]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.674290% CI: [-0.55, 0.96]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.448690% CI: [-0.79, 0.67]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.321990% CI: [-0.93, 0.53]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.009690% CI: [-2.21, -0.39]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.086290% CI: [-1.64, 0.15]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.011190% CI: [-2.15, -0.36]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.610790% CI: [-0.68, 0.97]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.72490% CI: [-0.54, 1.15]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.4390% CI: [-0.91, 0.74]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.050190% CI: [-1.66, 0]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.015790% CI: [-2.23, -0.3]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.064590% CI: [-1.83, 0.07]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.062190% CI: [-1.84, 0.06]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.295990% CI: [-1.21, 0.62]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.904390% CI: [-0.19, 1.69]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.201490% CI: [-1.38, 0.45]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.094890% CI: [-1.66, 0.19]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.041690% CI: [-2.21, -0.06]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.045490% CI: [-2.14, -0.03]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.025690% CI: [-2.31, -0.2]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.232690% CI: [-1.36, 0.53]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.514190% CI: [-0.95, 0.99]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.112490% CI: [-1.64, 0.25]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.098390% CI: [-1.7, 0.21]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.041290% CI: [-2.46, -0.07]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.03490% CI: [-2.47, -0.13]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.037990% CI: [-2.44, -0.09]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.129190% CI: [-1.91, 0.36]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.577690% CI: [-1.03, 1.3]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.104490% CI: [-2, 0.27]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.060890% CI: [-2.23, 0.07]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.030990% CI: [-2.84, -0.18]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.024290% CI: [-2.85, -0.26]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.039490% CI: [-2.69, -0.09]MMRM
Secondary
Change From Baseline in PASI Scores at Week 14 and 16
The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
Time frame: Baseline, Week 14 and 16
Population: EAS included all randomized participants who receive at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, number analyzed signifies the number of participants evaluable at specified time points.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Vehicle Once Daily (QD) | Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 6.12 Unit on a scale | Standard Deviation 2.87 |
| Vehicle Once Daily (QD) | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -0.46 Unit on a scale | Standard Deviation 2.603 |
| Vehicle Once Daily (QD) | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -0.83 Unit on a scale | Standard Deviation 2.379 |
| PF-06700841 0.1% QD | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -2.06 Unit on a scale | Standard Deviation 3.252 |
| PF-06700841 0.1% QD | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -2.24 Unit on a scale | Standard Deviation 2.945 |
| PF-06700841 0.1% QD | Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 7.19 Unit on a scale | Standard Deviation 3.37 |
| PF-06700841 0.3% QD | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -0.72 Unit on a scale | Standard Deviation 4.107 |
| PF-06700841 0.3% QD | Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 6.46 Unit on a scale | Standard Deviation 2.932 |
| PF-06700841 0.3% QD | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -0.78 Unit on a scale | Standard Deviation 4.223 |
| PF-06700841 1.0% QD | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -2.10 Unit on a scale | Standard Deviation 3.666 |
| PF-06700841 1.0% QD | Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 6.63 Unit on a scale | Standard Deviation 3.468 |
| PF-06700841 1.0% QD | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -1.81 Unit on a scale | Standard Deviation 3.228 |
| PF-06700841 3.0% QD | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -1.87 Unit on a scale | Standard Deviation 2.942 |
| PF-06700841 3.0% QD | Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 6.83 Unit on a scale | Standard Deviation 3.137 |
| PF-06700841 3.0% QD | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -1.68 Unit on a scale | Standard Deviation 3.255 |
| Pooled Vehicle BID | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -0.82 Unit on a scale | Standard Deviation 3.581 |
| Pooled Vehicle BID | Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 6.08 Unit on a scale | Standard Deviation 2.558 |
| Pooled Vehicle BID | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -0.67 Unit on a scale | Standard Deviation 4.008 |
| PF-06700841 0.3% BID | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -0.71 Unit on a scale | Standard Deviation 3.455 |
| PF-06700841 0.3% BID | Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 7.07 Unit on a scale | Standard Deviation 3.579 |
| PF-06700841 0.3% BID | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -1.04 Unit on a scale | Standard Deviation 3.732 |
| PF-06700841 1.0% BID | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -2.06 Unit on a scale | Standard Deviation 3.343 |
| PF-06700841 1.0% BID | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -1.75 Unit on a scale | Standard Deviation 3.887 |
| PF-06700841 1.0% BID | Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 5.80 Unit on a scale | Standard Deviation 2.765 |
| PF-06700841 3.0% BID | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -1.19 Unit on a scale | Standard Deviation 3.323 |
| PF-06700841 3.0% BID | Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -1.03 Unit on a scale | Standard Deviation 3.351 |
| PF-06700841 3.0% BID | Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 7.94 Unit on a scale | Standard Deviation 4.071 |
Secondary
Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12
Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10 and 12
Population: EAS included all randomized participants who receive at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure and 'number analyzed' signifies number of participants evaluable at specified time points.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Vehicle Once Daily (QD) | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -1.4 Unit on a scale | Standard Error 0.38 |
| Vehicle Once Daily (QD) | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -1.0 Unit on a scale | Standard Error 0.42 |
| Vehicle Once Daily (QD) | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -0.9 Unit on a scale | Standard Error 0.28 |
| Vehicle Once Daily (QD) | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -0.4 Unit on a scale | Standard Error 0.23 |
| Vehicle Once Daily (QD) | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -0.9 Unit on a scale | Standard Error 0.36 |
| Vehicle Once Daily (QD) | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -1.0 Unit on a scale | Standard Error 0.33 |
| Vehicle Once Daily (QD) | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -1.1 Unit on a scale | Standard Error 0.43 |
| PF-06700841 0.1% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -0.4 Unit on a scale | Standard Error 0.36 |
| PF-06700841 0.1% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -0.6 Unit on a scale | Standard Error 0.23 |
| PF-06700841 0.1% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -1.3 Unit on a scale | Standard Error 0.43 |
| PF-06700841 0.1% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -0.9 Unit on a scale | Standard Error 0.27 |
| PF-06700841 0.1% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -1.4 Unit on a scale | Standard Error 0.44 |
| PF-06700841 0.1% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -0.8 Unit on a scale | Standard Error 0.33 |
| PF-06700841 0.1% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -1.1 Unit on a scale | Standard Error 0.38 |
| PF-06700841 0.3% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -1.2 Unit on a scale | Standard Error 0.44 |
| PF-06700841 0.3% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -1.3 Unit on a scale | Standard Error 0.45 |
| PF-06700841 0.3% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -1.0 Unit on a scale | Standard Error 0.38 |
| PF-06700841 0.3% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -1.2 Unit on a scale | Standard Error 0.39 |
| PF-06700841 0.3% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -1.1 Unit on a scale | Standard Error 0.28 |
| PF-06700841 0.3% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -1.0 Unit on a scale | Standard Error 0.34 |
| PF-06700841 0.3% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -0.9 Unit on a scale | Standard Error 0.23 |
| PF-06700841 1.0% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -1.2 Unit on a scale | Standard Error 0.36 |
| PF-06700841 1.0% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -1.3 Unit on a scale | Standard Error 0.45 |
| PF-06700841 1.0% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -1.2 Unit on a scale | Standard Error 0.39 |
| PF-06700841 1.0% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -1.2 Unit on a scale | Standard Error 0.46 |
| PF-06700841 1.0% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -0.9 Unit on a scale | Standard Error 0.25 |
| PF-06700841 1.0% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -1.3 Unit on a scale | Standard Error 0.41 |
| PF-06700841 1.0% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -1.2 Unit on a scale | Standard Error 0.3 |
| PF-06700841 3.0% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -1.6 Unit on a scale | Standard Error 0.36 |
| PF-06700841 3.0% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -0.9 Unit on a scale | Standard Error 0.22 |
| PF-06700841 3.0% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -1.0 Unit on a scale | Standard Error 0.27 |
| PF-06700841 3.0% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -1.2 Unit on a scale | Standard Error 0.32 |
| PF-06700841 3.0% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -1.6 Unit on a scale | Standard Error 0.38 |
| PF-06700841 3.0% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -2.1 Unit on a scale | Standard Error 0.42 |
| PF-06700841 3.0% QD | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -1.8 Unit on a scale | Standard Error 0.42 |
| Pooled Vehicle BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -1.3 Unit on a scale | Standard Error 0.32 |
| Pooled Vehicle BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -0.5 Unit on a scale | Standard Error 0.39 |
| Pooled Vehicle BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -0.9 Unit on a scale | Standard Error 0.24 |
| Pooled Vehicle BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -1.2 Unit on a scale | Standard Error 0.38 |
| Pooled Vehicle BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -1.1 Unit on a scale | Standard Error 0.31 |
| Pooled Vehicle BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -0.6 Unit on a scale | Standard Error 0.41 |
| Pooled Vehicle BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -1.3 Unit on a scale | Standard Error 0.25 |
| PF-06700841 0.3% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -2.2 Unit on a scale | Standard Error 0.44 |
| PF-06700841 0.3% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -1.9 Unit on a scale | Standard Error 0.36 |
| PF-06700841 0.3% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -2.1 Unit on a scale | Standard Error 0.44 |
| PF-06700841 0.3% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -2.3 Unit on a scale | Standard Error 0.47 |
| PF-06700841 0.3% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -1.7 Unit on a scale | Standard Error 0.38 |
| PF-06700841 0.3% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -1.0 Unit on a scale | Standard Error 0.27 |
| PF-06700841 0.3% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -1.3 Unit on a scale | Standard Error 0.29 |
| PF-06700841 1.0% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -1.8 Unit on a scale | Standard Error 0.36 |
| PF-06700841 1.0% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -1.7 Unit on a scale | Standard Error 0.38 |
| PF-06700841 1.0% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -1.8 Unit on a scale | Standard Error 0.43 |
| PF-06700841 1.0% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -1.9 Unit on a scale | Standard Error 0.3 |
| PF-06700841 1.0% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -1.8 Unit on a scale | Standard Error 0.44 |
| PF-06700841 1.0% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -1.9 Unit on a scale | Standard Error 0.42 |
| PF-06700841 1.0% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -1.4 Unit on a scale | Standard Error 0.28 |
| PF-06700841 3.0% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -1.2 Unit on a scale | Standard Error 0.3 |
| PF-06700841 3.0% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -1.2 Unit on a scale | Standard Error 0.47 |
| PF-06700841 3.0% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -1.5 Unit on a scale | Standard Error 0.49 |
| PF-06700841 3.0% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -1.5 Unit on a scale | Standard Error 0.32 |
| PF-06700841 3.0% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -2.2 Unit on a scale | Standard Error 0.46 |
| PF-06700841 3.0% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -1.6 Unit on a scale | Standard Error 0.41 |
| PF-06700841 3.0% BID | Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -2.1 Unit on a scale | Standard Error 0.39 |
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.323290% CI: [-0.69, 0.39]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.073690% CI: [-1.03, 0.07]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.074390% CI: [-1.07, 0.07]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.064190% CI: [-1.03, 0.04]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.388790% CI: [-0.71, 0.5]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.076790% CI: [-1.15, 0.08]MMRM
Comparison: Week 1: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.252990% CI: [-0.89, 0.38]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.530490% CI: [-0.61, 0.67]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.29290% CI: [-0.87, 0.43]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.259390% CI: [-0.7, 0.57]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.43190% CI: [-0.7, 0.57]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.547790% CI: [-0.59, 0.69]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.069690% CI: [-1.24, 0.07]MMRM
Comparison: Week 2: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.358390% CI: [-0.82, 0.53]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.682690% CI: [-0.56, 1.01]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.45790% CI: [-0.84, 0.74]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.326590% CI: [-1.03, 0.59]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.303990% CI: [-1, 0.53]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.208690% CI: [-1.23, 0.42]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.217290% CI: [-1.22, 0.44]MMRM
Comparison: Week 4: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.285590% CI: [-1.16, 0.57]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.837290% CI: [-0.34, 1.36]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.479290% CI: [-0.89, 0.84]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.333190% CI: [-1.12, 0.65]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.10890% CI: [-1.47, 0.21]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.045590% CI: [-1.61, -0.02]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.076190% CI: [-1.49, 0.1]MMRM
Comparison: Week 6: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.027390% CI: [-1.8, -0.14]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.721490% CI: [-0.57, 1.2]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.613290% CI: [-0.75, 1.06]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.570490% CI: [-0.83, 1.02]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.344990% CI: [-1.1, 0.67]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.049390% CI: [-1.94, 0]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.14990% CI: [-1.55, 0.35]MMRM
Comparison: Week 8: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.05490% CI: [-1.96, 0.02]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.311990% CI: [-1.32, 0.71]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.394790% CI: [-1.2, 0.86]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.420590% CI: [-1.18, 0.93]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.047290% CI: [-2.02, -0.02]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.004490% CI: [-2.55, -0.6]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.009890% CI: [-2.32, -0.41]MMRM
Comparison: Week 10: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.128590% CI: [-1.71, 0.32]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.324390% CI: [-1.27, 0.72]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.379590% CI: [-1.2, 0.82]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.30790% CI: [-1.35, 0.72]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.101490% CI: [-1.74, 0.22]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.003390% CI: [-2.75, -0.69]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.02890% CI: [-2.18, -0.17]MMRM
Comparison: Week 12: MMRM analysis contained treatment, visit, and treatment by visit interaction as fixed factors, and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.078190% CI: [-1.98, 0.15]MMRM
Secondary
Change From Baseline in PP-NRS Score at Week 14 and 16
Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch.
Time frame: Baseline, Week 14 and 16
Population: EAS included all randomized participants who receive at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure and 'number analyzed' signifies number of participants evaluable at specified time points.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Vehicle Once Daily (QD) | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 16 | -0.6 Unit on a scale | Standard Deviation 2.97 |
| Vehicle Once Daily (QD) | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 14 | -0.4 Unit on a scale | Standard Deviation 3.18 |
| PF-06700841 0.1% QD | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 16 | -0.9 Unit on a scale | Standard Deviation 1.82 |
| PF-06700841 0.1% QD | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 14 | -1.4 Unit on a scale | Standard Deviation 1.64 |
| PF-06700841 0.3% QD | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 14 | -1.8 Unit on a scale | Standard Deviation 3.16 |
| PF-06700841 0.3% QD | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 16 | -1.2 Unit on a scale | Standard Deviation 3.21 |
| PF-06700841 1.0% QD | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 16 | -0.7 Unit on a scale | Standard Deviation 2.02 |
| PF-06700841 1.0% QD | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 14 | -1.2 Unit on a scale | Standard Deviation 2.52 |
| PF-06700841 3.0% QD | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 14 | -1.1 Unit on a scale | Standard Deviation 2.38 |
| PF-06700841 3.0% QD | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 16 | -1.0 Unit on a scale | Standard Deviation 2.52 |
| Pooled Vehicle BID | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 16 | -0.9 Unit on a scale | Standard Deviation 2.99 |
| Pooled Vehicle BID | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 14 | -1.0 Unit on a scale | Standard Deviation 2.93 |
| PF-06700841 0.3% BID | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 14 | -1.1 Unit on a scale | Standard Deviation 2.57 |
| PF-06700841 0.3% BID | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 16 | -1.0 Unit on a scale | Standard Deviation 2.29 |
| PF-06700841 1.0% BID | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 14 | -1.3 Unit on a scale | Standard Deviation 2.31 |
| PF-06700841 1.0% BID | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 16 | -0.9 Unit on a scale | Standard Deviation 2.25 |
| PF-06700841 3.0% BID | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 14 | -0.1 Unit on a scale | Standard Deviation 4.18 |
| PF-06700841 3.0% BID | Change From Baseline in PP-NRS Score at Week 14 and 16 | Change at Week 16 | 0.4 Unit on a scale | Standard Deviation 3.54 |
Secondary
Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2
PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET (Prior to Week 12), ET Follow-up Visit 1 (2 weeks post ET) and 2 (4 weeks post ET)
Population: EAS included all randomized participants who receive at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure and 'number analyzed' signifies number of participants evaluable at specified time points.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Vehicle Once Daily (QD) | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 8 | -4.1 Unit on a scale | Standard Deviation 7.2 |
| Vehicle Once Daily (QD) | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 1 | -3.3 Unit on a scale | Standard Deviation 4.94 |
| Vehicle Once Daily (QD) | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 16 | -0.9 Unit on a scale | Standard Deviation 7.61 |
| Vehicle Once Daily (QD) | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 10 | -4.0 Unit on a scale | Standard Deviation 7.57 |
| Vehicle Once Daily (QD) | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 14 | -0.7 Unit on a scale | Standard Deviation 7.86 |
| Vehicle Once Daily (QD) | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 2 | -4.0 Unit on a scale | Standard Deviation 5.46 |
| Vehicle Once Daily (QD) | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 4 | -3.0 Unit on a scale | Standard Deviation 6.33 |
| Vehicle Once Daily (QD) | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 1 | -2.5 Unit on a scale | Standard Deviation 0.71 |
| Vehicle Once Daily (QD) | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 12 | -3.8 Unit on a scale | Standard Deviation 7.74 |
| Vehicle Once Daily (QD) | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 6 | -3.5 Unit on a scale | Standard Deviation 7.09 |
| Vehicle Once Daily (QD) | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET | -2.7 Unit on a scale | Standard Deviation 2.52 |
| Vehicle Once Daily (QD) | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 2 | -1.5 Unit on a scale | Standard Deviation 2.12 |
| PF-06700841 0.1% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 4 | -3.4 Unit on a scale | Standard Deviation 5.09 |
| PF-06700841 0.1% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 8 | -3.5 Unit on a scale | Standard Deviation 4.6 |
| PF-06700841 0.1% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 1 | -9.0 Unit on a scale | — |
| PF-06700841 0.1% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 2 | -3.9 Unit on a scale | Standard Deviation 4.91 |
| PF-06700841 0.1% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 12 | -4.1 Unit on a scale | Standard Deviation 4.98 |
| PF-06700841 0.1% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET | 0.7 Unit on a scale | Standard Deviation 6.11 |
| PF-06700841 0.1% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 1 | -2.8 Unit on a scale | Standard Deviation 3.35 |
| PF-06700841 0.1% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 2 | -11.0 Unit on a scale | — |
| PF-06700841 0.1% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 14 | -2.9 Unit on a scale | Standard Deviation 4.68 |
| PF-06700841 0.1% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 16 | -2.4 Unit on a scale | Standard Deviation 5.02 |
| PF-06700841 0.1% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 10 | -4.0 Unit on a scale | Standard Deviation 4.9 |
| PF-06700841 0.1% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 6 | -3.1 Unit on a scale | Standard Deviation 5.3 |
| PF-06700841 0.3% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 10 | -3.4 Unit on a scale | Standard Deviation 6.24 |
| PF-06700841 0.3% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 6 | -2.0 Unit on a scale | Standard Deviation 6.2 |
| PF-06700841 0.3% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 12 | -3.2 Unit on a scale | Standard Deviation 5.63 |
| PF-06700841 0.3% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 1 | -5.0 Unit on a scale | Standard Deviation 7.07 |
| PF-06700841 0.3% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 2 | -6.5 Unit on a scale | Standard Deviation 4.95 |
| PF-06700841 0.3% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 4 | -3.5 Unit on a scale | Standard Deviation 5.12 |
| PF-06700841 0.3% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 1 | -3.0 Unit on a scale | Standard Deviation 3.84 |
| PF-06700841 0.3% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 16 | -3.2 Unit on a scale | Standard Deviation 6.37 |
| PF-06700841 0.3% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 8 | -3.2 Unit on a scale | Standard Deviation 6.56 |
| PF-06700841 0.3% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET | -1.0 Unit on a scale | Standard Deviation 8.29 |
| PF-06700841 0.3% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 2 | -4.1 Unit on a scale | Standard Deviation 4.36 |
| PF-06700841 0.3% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 14 | -4.4 Unit on a scale | Standard Deviation 7.49 |
| PF-06700841 1.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 6 | -3.5 Unit on a scale | Standard Deviation 5.22 |
| PF-06700841 1.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 2 | -4.0 Unit on a scale | — |
| PF-06700841 1.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 12 | -3.7 Unit on a scale | Standard Deviation 6.13 |
| PF-06700841 1.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 2 | -3.1 Unit on a scale | Standard Deviation 3.63 |
| PF-06700841 1.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 1 | -4.0 Unit on a scale | — |
| PF-06700841 1.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 4 | -2.6 Unit on a scale | Standard Deviation 3.91 |
| PF-06700841 1.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET | 0.3 Unit on a scale | Standard Deviation 2.08 |
| PF-06700841 1.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 10 | -3.3 Unit on a scale | Standard Deviation 6.12 |
| PF-06700841 1.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 1 | -2.6 Unit on a scale | Standard Deviation 2.95 |
| PF-06700841 1.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 16 | -2.4 Unit on a scale | Standard Deviation 7.27 |
| PF-06700841 1.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 8 | -3.7 Unit on a scale | Standard Deviation 5.01 |
| PF-06700841 1.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 14 | -3.1 Unit on a scale | Standard Deviation 6.87 |
| PF-06700841 3.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 1 | -3.0 Unit on a scale | — |
| PF-06700841 3.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 1 | -3.4 Unit on a scale | Standard Deviation 4.17 |
| PF-06700841 3.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 2 | -3.8 Unit on a scale | Standard Deviation 4.62 |
| PF-06700841 3.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 4 | -4.1 Unit on a scale | Standard Deviation 4.55 |
| PF-06700841 3.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 6 | -4.0 Unit on a scale | Standard Deviation 4.64 |
| PF-06700841 3.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 8 | -4.1 Unit on a scale | Standard Deviation 5.01 |
| PF-06700841 3.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 10 | -5.3 Unit on a scale | Standard Deviation 5.69 |
| PF-06700841 3.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 12 | -5.2 Unit on a scale | Standard Deviation 6.04 |
| PF-06700841 3.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 14 | -2.2 Unit on a scale | Standard Deviation 5.49 |
| PF-06700841 3.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 16 | -2.1 Unit on a scale | Standard Deviation 6.05 |
| PF-06700841 3.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET | -1.3 Unit on a scale | Standard Deviation 6.85 |
| PF-06700841 3.0% QD | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 2 | 6.5 Unit on a scale | Standard Deviation 9.19 |
| Pooled Vehicle BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 8 | -5.2 Unit on a scale | Standard Deviation 8.12 |
| Pooled Vehicle BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 6 | -5.1 Unit on a scale | Standard Deviation 7.4 |
| Pooled Vehicle BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 16 | -2.6 Unit on a scale | Standard Deviation 7.12 |
| Pooled Vehicle BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 10 | -5.5 Unit on a scale | Standard Deviation 8.08 |
| Pooled Vehicle BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 1 | 2.0 Unit on a scale | Standard Deviation 9.9 |
| Pooled Vehicle BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 2 | -5.1 Unit on a scale | Standard Deviation 5.85 |
| Pooled Vehicle BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 12 | -5.0 Unit on a scale | Standard Deviation 8.15 |
| Pooled Vehicle BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 2 | 0.8 Unit on a scale | Standard Deviation 7.14 |
| Pooled Vehicle BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 14 | -3.5 Unit on a scale | Standard Deviation 7.87 |
| Pooled Vehicle BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 1 | -3.9 Unit on a scale | Standard Deviation 5 |
| Pooled Vehicle BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 4 | -3.9 Unit on a scale | Standard Deviation 6.5 |
| Pooled Vehicle BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET | 0.7 Unit on a scale | Standard Deviation 5.16 |
| PF-06700841 0.3% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 4 | -4.6 Unit on a scale | Standard Deviation 5.44 |
| PF-06700841 0.3% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 8 | -5.8 Unit on a scale | Standard Deviation 5.35 |
| PF-06700841 0.3% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 14 | -1.4 Unit on a scale | Standard Deviation 5.53 |
| PF-06700841 0.3% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 6 | -6.3 Unit on a scale | Standard Deviation 5.05 |
| PF-06700841 0.3% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 2 | -11.0 Unit on a scale | Standard Deviation 4.24 |
| PF-06700841 0.3% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 16 | -0.8 Unit on a scale | Standard Deviation 4.29 |
| PF-06700841 0.3% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 12 | -5.2 Unit on a scale | Standard Deviation 4.82 |
| PF-06700841 0.3% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET | 1.8 Unit on a scale | Standard Deviation 7.4 |
| PF-06700841 0.3% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 2 | -4.2 Unit on a scale | Standard Deviation 3.91 |
| PF-06700841 0.3% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 1 | -2.5 Unit on a scale | Standard Deviation 0.71 |
| PF-06700841 0.3% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 1 | -3.7 Unit on a scale | Standard Deviation 3.49 |
| PF-06700841 0.3% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 10 | -5.1 Unit on a scale | Standard Deviation 5.12 |
| PF-06700841 1.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 4 | -3.7 Unit on a scale | Standard Deviation 4.57 |
| PF-06700841 1.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 2 | -0.3 Unit on a scale | Standard Deviation 8.26 |
| PF-06700841 1.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET | -4.0 Unit on a scale | Standard Deviation 3 |
| PF-06700841 1.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 14 | -2.3 Unit on a scale | Standard Deviation 4.98 |
| PF-06700841 1.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 2 | -4.3 Unit on a scale | Standard Deviation 4.12 |
| PF-06700841 1.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 10 | -3.9 Unit on a scale | Standard Deviation 4.82 |
| PF-06700841 1.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 8 | -3.2 Unit on a scale | Standard Deviation 4.9 |
| PF-06700841 1.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 12 | -3.7 Unit on a scale | Standard Deviation 5.67 |
| PF-06700841 1.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 1 | -7.0 Unit on a scale | — |
| PF-06700841 1.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 1 | -3.4 Unit on a scale | Standard Deviation 3.18 |
| PF-06700841 1.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 6 | -3.4 Unit on a scale | Standard Deviation 4.6 |
| PF-06700841 1.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 16 | -0.8 Unit on a scale | Standard Deviation 5.28 |
| PF-06700841 3.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 12 | -6.6 Unit on a scale | Standard Deviation 7.82 |
| PF-06700841 3.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 16 | -2.7 Unit on a scale | Standard Deviation 8.4 |
| PF-06700841 3.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 14 | -2.9 Unit on a scale | Standard Deviation 7.98 |
| PF-06700841 3.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 10 | -5.8 Unit on a scale | Standard Deviation 7.62 |
| PF-06700841 3.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 1 | -9.0 Unit on a scale | — |
| PF-06700841 3.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET | -5.0 Unit on a scale | Standard Deviation 1.41 |
| PF-06700841 3.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 1 | -6.6 Unit on a scale | Standard Deviation 4.8 |
| PF-06700841 3.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 2 | -7.8 Unit on a scale | Standard Deviation 5.37 |
| PF-06700841 3.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 6 | -6.5 Unit on a scale | Standard Deviation 5.75 |
| PF-06700841 3.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 4 | -6.5 Unit on a scale | Standard Deviation 5.44 |
| PF-06700841 3.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at ET Follow-up Visit 2 | -1.0 Unit on a scale | Standard Deviation 9.9 |
| PF-06700841 3.0% BID | Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 | Change at Week 8 | -7.0 Unit on a scale | Standard Deviation 6.64 |
Secondary
Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16
At the site of study drug application, skin tolerability was assessed for non-lesional skin surrounding the plaques on a scale from 0 to 4. Grade 0= none (no evidence of local intolerance), Grade 1= mild (minimal erythema and/or edema, slight glazed appearance), Grade 2= moderate (definite erythema and/or oedema with peeling and/or cracking but needs no adaptation of posology), Grade 3= severe, reported as AE (erythema, oedema glazing with fissures, few vesicles or papules: consider removing topical agent \[if still in place\]), Grade 4= very severe, reported as AE (strong reaction spreading beyond the treated area, bullous reaction, erosions: removal of topical agent \[if still in place\]).
Time frame: Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16
Population: SAS included participants who receive at least 1 dose of investigational product. Here, number analyzed signifies the number of participants evaluable at specified time points.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Mild | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | None | 32 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Missing | 3 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Missing | 1 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Moderate | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Very severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Missing | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Mild | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Very severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Mild | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Mild | 1 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Missing | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Very severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | None | 31 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Missing | 4 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Missing | 2 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Very severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | None | 36 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Moderate | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Very severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Very severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | None | 29 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | None | 33 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Mild | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Moderate | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Mild | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | None | 32 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Moderate | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Very severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | None | 29 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Very severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Missing | 5 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Mild | 1 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Moderate | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Very severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | None | 33 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Missing | 3 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Moderate | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Very severe | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Moderate | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Missing | 1 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Mild | 1 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Mild | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Moderate | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Mild | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Moderate | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | None | 31 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | None | 34 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Moderate | 1 Participants |
| Vehicle Once Daily (QD) | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Missing | 3 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Moderate | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Missing | 1 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Mild | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Very severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Missing | 1 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Very severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Very severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Mild | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Moderate | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Mild | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Missing | 7 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Moderate | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Very severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | None | 31 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | None | 35 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Mild | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Missing | 2 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | None | 28 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | None | 35 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | None | 30 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | None | 32 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Mild | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Very severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Mild | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Missing | 1 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Moderate | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Missing | 1 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Moderate | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Moderate | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Very severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Moderate | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Very severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Very severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Moderate | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Very severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | None | 37 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Missing | 4 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Mild | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Missing | 7 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Missing | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | None | 30 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Mild | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Very severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Mild | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Mild | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Missing | 2 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Moderate | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | None | 32 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | None | 27 Participants |
| PF-06700841 0.1% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Moderate | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Missing | 5 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Moderate | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Very severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Moderate | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | None | 36 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Mild | 1 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Mild | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Missing | 10 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | None | 26 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | None | 30 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Mild | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Missing | 6 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Missing | 7 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Moderate | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Very severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Very severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Moderate | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Very severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Mild | 1 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Missing | 9 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Very severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | None | 24 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Missing | 5 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Mild | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Moderate | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Very severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | None | 29 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | None | 24 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Missing | 5 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Mild | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Moderate | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Moderate | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Very severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Mild | 1 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | None | 30 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | None | 26 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Missing | 6 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Mild | 1 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Missing | 4 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Very severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Very severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Moderate | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Very severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Moderate | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Mild | 1 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | None | 27 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | None | 32 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Mild | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Missing | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Moderate | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | None | 29 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Very severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | None | 32 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Moderate | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Moderate | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Very severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Moderate | 1 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Missing | 1 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Mild | 2 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | None | 29 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Mild | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Missing | 1 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Mild | 1 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Very severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Moderate | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Missing | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Very severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Moderate | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Very severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Missing | 7 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Very severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Moderate | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | None | 36 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Missing | 4 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Moderate | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Mild | 2 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Very severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Missing | 3 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Mild | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | None | 31 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Missing | 3 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | None | 30 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Moderate | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | None | 34 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | None | 34 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Missing | 4 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Mild | 1 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Very severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Very severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | None | 30 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | None | 28 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Moderate | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Missing | 5 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Missing | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Moderate | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Mild | 1 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Mild | 1 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Very severe | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Mild | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Mild | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Moderate | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Very severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Moderate | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Missing | 4 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | None | 28 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Mild | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Moderate | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Missing | 4 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Very severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Missing | 4 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Missing | 4 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | None | 30 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Mild | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Moderate | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Very severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Missing | 1 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | None | 27 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Mild | 1 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Moderate | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Very severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Missing | 3 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | None | 26 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Mild | 1 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Moderate | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Very severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | None | 36 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Mild | 1 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Moderate | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Very severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Missing | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | None | 35 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Mild | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Very severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Missing | 2 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | None | 35 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Mild | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Moderate | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Very severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Missing | 1 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | None | 34 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Mild | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | None | 27 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Mild | 1 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Moderate | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Very severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Missing | 3 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | None | 30 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Mild | 1 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Moderate | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Very severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | None | 44 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Mild | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Mild | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Missing | 2 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Mild | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Missing | 4 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Very severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Very severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Moderate | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Moderate | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Mild | 1 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | None | 34 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Missing | 2 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | None | 45 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Missing | 11 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Very severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | None | 44 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | None | 43 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | None | 35 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Mild | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Missing | 6 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Moderate | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Missing | 7 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Moderate | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Mild | 1 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Very severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Moderate | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Very severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Missing | 10 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Mild | 1 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Very severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Moderate | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Moderate | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Very severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Moderate | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Very severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Missing | 1 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Mild | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | None | 34 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Very severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | None | 34 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Moderate | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | None | 48 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Moderate | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Missing | 6 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Mild | 1 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Very severe | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Mild | 0 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | None | 37 Participants |
| Pooled Vehicle BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Missing | 3 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Very severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Moderate | 1 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Very severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Mild | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Missing | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | None | 26 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | None | 32 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Missing | 3 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Mild | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Very severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Moderate | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Moderate | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Very severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Mild | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Missing | 4 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | None | 28 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Missing | 2 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | None | 34 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Very severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Mild | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Moderate | 1 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Moderate | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Mild | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Mild | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Very severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Missing | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | None | 26 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Missing | 3 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Missing | 3 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | None | 30 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | None | 24 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Very severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Mild | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Moderate | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Moderate | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Very severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Missing | 8 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Mild | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Missing | 4 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | None | 26 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Missing | 8 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | None | 30 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Very severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Mild | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | None | 35 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Moderate | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Mild | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Very severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Moderate | 1 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Moderate | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Missing | 1 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Missing | 3 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | None | 36 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | None | 28 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Mild | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Very severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Very severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Mild | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Missing | 4 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Moderate | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | None | 32 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Missing | 9 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | None | 27 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Very severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Mild | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Mild | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Moderate | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Missing | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Moderate | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Moderate | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Very severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Moderate | 1 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Missing | 6 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Very severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Mild | 2 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Very severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Very severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Mild | 1 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Mild | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Missing | 4 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Missing | 7 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Moderate | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | None | 32 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | None | 32 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Very severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | None | 35 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Missing | 3 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Mild | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | None | 31 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | None | 30 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Moderate | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Moderate | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Mild | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Mild | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Missing | 2 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Very severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Very severe | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | None | 26 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Moderate | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Moderate | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Missing | 2 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | None | 37 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Missing | 5 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Very severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Missing | 2 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Mild | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Very severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | None | 28 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Very severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Missing | 5 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Very severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Mild | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Mild | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Missing | 4 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Mild | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | None | 30 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Missing | 4 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Very severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Missing | 2 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Missing | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | None | 26 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | None | 26 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | None | 33 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Very severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Moderate | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | None | 35 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Mild | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Moderate | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Moderate | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Moderate | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Mild | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Day1 | Mild | 1 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Moderate | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | None | 29 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | None | 28 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 12 | Moderate | 1 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Moderate | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Moderate | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Very severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 16 | Missing | 7 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Very severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Mild | 3 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | None | 30 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Missing | 1 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 10 | Severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 8 | Moderate | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 2 | Mild | 2 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 6 | Very severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Very severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 4 | Severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 1 | Mild | 1 Participants |
| PF-06700841 3.0% BID | Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Day 1, Week 1, 2, 4, 6, 8, 10, 12, 14, 16 | Week 14 | Moderate | 0 Participants |
Secondary
Number of Participants Who Discontinued From Study Due to Adverse Events
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.
Time frame: Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)
Population: SAS included participants who received at least 1 dose of investigational product.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Vehicle Once Daily (QD) | Number of Participants Who Discontinued From Study Due to Adverse Events | 1 Participants |
| PF-06700841 0.1% QD | Number of Participants Who Discontinued From Study Due to Adverse Events | 1 Participants |
| PF-06700841 0.3% QD | Number of Participants Who Discontinued From Study Due to Adverse Events | 3 Participants |
| PF-06700841 1.0% QD | Number of Participants Who Discontinued From Study Due to Adverse Events | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants Who Discontinued From Study Due to Adverse Events | 2 Participants |
| Pooled Vehicle BID | Number of Participants Who Discontinued From Study Due to Adverse Events | 1 Participants |
| PF-06700841 0.3% BID | Number of Participants Who Discontinued From Study Due to Adverse Events | 1 Participants |
| PF-06700841 1.0% BID | Number of Participants Who Discontinued From Study Due to Adverse Events | 2 Participants |
| PF-06700841 3.0% BID | Number of Participants Who Discontinued From Study Due to Adverse Events | 1 Participants |
Secondary
Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data
Following were ECG criteria used for categorical summary:1) PR interval: percentage change \>=25/50%, QRS interval: value \>140 msec, and QT interval corrected using the Fridericia's formula (QTcF): 450 msec \< value less than equal to (\<=) 480 and 30 \< change \<=60.
Time frame: Post-baseline to Week 6, Post-baseline to Week 12
Population: SAS included participants who receive at least 1 dose of investigational product
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QRS interval (>=140 msec) | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (30 < Chg <= 60) | 2 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QRS interval (>=140 msec) | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: PR interval (>=25/50 percent) | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QTcF interval (30< Change <=60) | 1 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (450< Value <=480) | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: PR interval (>=25/50 percent) | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: PR interval (>=25/50 percent) | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QRS interval (>=140 msec) | 1 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (30 < Chg <= 60) | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (450< Value <=480) | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QTcF interval (30< Change <=60) | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: PR interval (>=25/50 percent) | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QRS interval (>=140 msec) | 1 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QRS interval (>=140 msec) | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (450< Value <=480) | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: PR interval (>=25/50 percent) | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (30 < Chg <= 60) | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: PR interval (>=25/50 percent) | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QTcF interval (30< Change <=60) | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QRS interval (>=140 msec) | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QTcF interval (30< Change <=60) | 1 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: PR interval (>=25/50 percent) | 1 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (450< Value <=480) | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: PR interval (>=25/50 percent) | 1 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QRS interval (>=140 msec) | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (30 < Chg <= 60) | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QRS interval (>=140 msec) | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: PR interval (>=25/50 percent) | 1 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: PR interval (>=25/50 percent) | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QRS interval (>=140 msec) | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QTcF interval (30< Change <=60) | 1 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QRS interval (>=140 msec) | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (450< Value <=480) | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (30 < Chg <= 60) | 0 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QTcF interval (30< Change <=60) | 0 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (450< Value <=480) | 2 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: PR interval (>=25/50 percent) | 1 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QRS interval (>=140 msec) | 2 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: PR interval (>=25/50 percent) | 1 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (30 < Chg <= 60) | 2 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QRS interval (>=140 msec) | 1 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QRS interval (>=140 msec) | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: PR interval (>=25/50 percent) | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (450< Value <=480) | 1 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (30 < Chg <= 60) | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QTcF interval (30< Change <=60) | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: PR interval (>=25/50 percent) | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QRS interval (>=140 msec) | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: PR interval (>=25/50 percent) | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QTcF interval (30< Change <=60) | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QRS interval (>=140 msec) | 1 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QRS interval (>=140 msec) | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (30 < Chg <= 60) | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (450< Value <=480) | 1 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: PR interval (>=25/50 percent) | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: PR interval (>=25/50 percent) | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (450< Value <=480) | 1 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QTcF interval (30 < Chg <= 60) | 1 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QRS interval (>=140 msec) | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: QRS interval (>=140 msec) | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 6: QTcF interval (30< Change <=60) | 2 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data | Post-baseline to Week 12: PR interval (>=25/50 percent) | 0 Participants |
Secondary
Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data
Following were the vital signs criteria: 1) Pulse rate: value \<40 beats per min (bpm), value \>120 bpm; 2) Sitting diastolic blood pressure (DBP): value \<50 mmHg; change \>=20 mmHg increase; change \>=20 mmHg decrease; 3) Sitting systolic blood pressure (SBP): value \<90 mmHg, change \>=30 mmHg increase, change \>=30 mmHg decrease; 4) Supine DBP: value \<50 mmHg, change \>=20 mmHg increase, change \>=20 mmHg decrease; 5) Supine SBP: value \<90 mmHg, change \>=30 mmHg increase, change \>=30 mmHg decrease.
Time frame: Post-baseline to Week 12
Population: SAS included participants who receive at least 1 dose of investigational product. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure and 'number analyzed' signifies number of participants evaluable at specified time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>= 30 mmHg decrease) | 1 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>=20 mmHg decrease) | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg decrease) | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>=30 mmHg increase) | 1 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (<50 mmHg) | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>= 20mmHg increase) | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate >120 bpm | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>= 30 mmHg increase) | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (<50 mmHg) | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (<90 mmHg) | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>=30 mmHg decrease) | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate < 40 bpm | 0 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (<90 mmHg) | 1 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg increase) | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (<50 mmHg) | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>= 30 mmHg decrease) | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>= 20mmHg increase) | 1 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>=20 mmHg decrease) | 2 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg decrease) | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate >120 bpm | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg increase) | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>= 30 mmHg increase) | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>=30 mmHg increase) | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (<50 mmHg) | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>=30 mmHg decrease) | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (<90 mmHg) | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate < 40 bpm | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (<90 mmHg) | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>= 30 mmHg increase) | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>= 30 mmHg decrease) | 1 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>=30 mmHg decrease) | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate >120 bpm | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>=30 mmHg increase) | 1 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (<50 mmHg) | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (<90 mmHg) | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg increase) | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate < 40 bpm | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>=20 mmHg decrease) | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg decrease) | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>= 20mmHg increase) | 1 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (<90 mmHg) | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (<50 mmHg) | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate >120 bpm | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>=20 mmHg decrease) | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg increase) | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (<90 mmHg) | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (<50 mmHg) | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>=30 mmHg decrease) | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (<90 mmHg) | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>= 30 mmHg decrease) | 1 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (<50 mmHg) | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>= 30 mmHg increase) | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>=30 mmHg increase) | 2 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg decrease) | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate < 40 bpm | 0 Participants |
| PF-06700841 1.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>= 20mmHg increase) | 1 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate < 40 bpm | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate >120 bpm | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (<50 mmHg) | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg increase) | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg decrease) | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (<90 mmHg) | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>= 30 mmHg increase) | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>=30 mmHg decrease) | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (<50 mmHg) | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>= 20mmHg increase) | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>=20 mmHg decrease) | 1 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (<90 mmHg) | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>=30 mmHg increase) | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>= 30 mmHg decrease) | 0 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg decrease) | 0 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>= 30 mmHg decrease) | 0 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>= 20mmHg increase) | 0 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>=30 mmHg decrease) | 0 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg increase) | 0 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (<90 mmHg) | 0 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate < 40 bpm | 0 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (<50 mmHg) | 0 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>= 30 mmHg increase) | 0 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate >120 bpm | 0 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (<90 mmHg) | 0 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (<50 mmHg) | 0 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>=20 mmHg decrease) | 4 Participants |
| Pooled Vehicle BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>=30 mmHg increase) | 2 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>=30 mmHg decrease) | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (<90 mmHg) | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (<50 mmHg) | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg decrease) | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>= 20mmHg increase) | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg increase) | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>=20 mmHg decrease) | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (<50 mmHg) | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>= 30 mmHg decrease) | 1 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (<90 mmHg) | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate >120 bpm | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>=30 mmHg increase) | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>= 30 mmHg increase) | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate < 40 bpm | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>=20 mmHg decrease) | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (<50 mmHg) | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>= 30 mmHg increase) | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (<90 mmHg) | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate >120 bpm | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (<50 mmHg) | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>= 30 mmHg decrease) | 1 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (<90 mmHg) | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>=30 mmHg decrease) | 1 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>=30 mmHg increase) | 2 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg increase) | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>= 20mmHg increase) | 2 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg decrease) | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate < 40 bpm | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg increase) | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (<50 mmHg) | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>= 30 mmHg decrease) | 1 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>= 30 mmHg increase) | 1 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting DBP (>=20 mmHg decrease) | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate < 40 bpm | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (<50 mmHg) | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (>=30 mmHg decrease) | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>=20 mmHg decrease) | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (<90 mmHg) | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Pulse rate >120 bpm | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine SBP (>=30 mmHg increase) | 1 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Sitting SBP (<90 mmHg) | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data | Supine DBP (>= 20mmHg increase) | 2 Participants |
Secondary
Number of Participants With Laboratory Abnormalities Meeting Specified Criteria
Bilirubin: greater than (\>) 1.5\* upper limit normal (ULN); aspartate aminotransferase, alanine aminotransferase: \>2.5\*ULN; creatinine, cystatin C: \>1.3\*ULN; creatine kinase: \>2.0\*ULN; glomerular filtration rate (GFR) CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Equat: less than (\<) 60 milliliter (mL)/minute (min)/1.73 meter(m)\^2, greater than or equal to (\>=) 30% decrease from baseline; GFR: \<60 mL/min/1.73m\^2.
Time frame: Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)
Population: SAS included participants who received at least 1 dose of investigational product. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Vehicle Once Daily (QD) | Number of Participants With Laboratory Abnormalities Meeting Specified Criteria | 7 Participants |
| PF-06700841 0.1% QD | Number of Participants With Laboratory Abnormalities Meeting Specified Criteria | 6 Participants |
| PF-06700841 0.3% QD | Number of Participants With Laboratory Abnormalities Meeting Specified Criteria | 11 Participants |
| PF-06700841 1.0% QD | Number of Participants With Laboratory Abnormalities Meeting Specified Criteria | 7 Participants |
| PF-06700841 3.0% QD | Number of Participants With Laboratory Abnormalities Meeting Specified Criteria | 5 Participants |
| Pooled Vehicle BID | Number of Participants With Laboratory Abnormalities Meeting Specified Criteria | 12 Participants |
| PF-06700841 0.3% BID | Number of Participants With Laboratory Abnormalities Meeting Specified Criteria | 5 Participants |
| PF-06700841 1.0% BID | Number of Participants With Laboratory Abnormalities Meeting Specified Criteria | 6 Participants |
| PF-06700841 3.0% BID | Number of Participants With Laboratory Abnormalities Meeting Specified Criteria | 15 Participants |
Secondary
Number of Participants With TEAEs by Severity
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. AE was assessed according to severity; mild (not causing any significant problem, dose adjustment not required), moderate (caused problem that does not interfere significantly with usual activities or the clinical status, dose adjustment needed due to adverse event) and severe (caused problem that interfered significantly with usual activities or the clinical status, study drug stopped due to adverse event).
Time frame: Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)
Population: SAS included participants who received at least 1 dose of investigational product.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Vehicle Once Daily (QD) | Number of Participants With TEAEs by Severity | Moderate | 5 Participants |
| Vehicle Once Daily (QD) | Number of Participants With TEAEs by Severity | Mild | 12 Participants |
| Vehicle Once Daily (QD) | Number of Participants With TEAEs by Severity | Severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With TEAEs by Severity | Mild | 9 Participants |
| PF-06700841 0.1% QD | Number of Participants With TEAEs by Severity | Severe | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With TEAEs by Severity | Moderate | 7 Participants |
| PF-06700841 0.3% QD | Number of Participants With TEAEs by Severity | Moderate | 3 Participants |
| PF-06700841 0.3% QD | Number of Participants With TEAEs by Severity | Severe | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With TEAEs by Severity | Mild | 11 Participants |
| PF-06700841 1.0% QD | Number of Participants With TEAEs by Severity | Moderate | 5 Participants |
| PF-06700841 1.0% QD | Number of Participants With TEAEs by Severity | Severe | 1 Participants |
| PF-06700841 1.0% QD | Number of Participants With TEAEs by Severity | Mild | 11 Participants |
| PF-06700841 3.0% QD | Number of Participants With TEAEs by Severity | Severe | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With TEAEs by Severity | Mild | 7 Participants |
| PF-06700841 3.0% QD | Number of Participants With TEAEs by Severity | Moderate | 7 Participants |
| Pooled Vehicle BID | Number of Participants With TEAEs by Severity | Severe | 1 Participants |
| Pooled Vehicle BID | Number of Participants With TEAEs by Severity | Mild | 8 Participants |
| Pooled Vehicle BID | Number of Participants With TEAEs by Severity | Moderate | 11 Participants |
| PF-06700841 0.3% BID | Number of Participants With TEAEs by Severity | Severe | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With TEAEs by Severity | Moderate | 6 Participants |
| PF-06700841 0.3% BID | Number of Participants With TEAEs by Severity | Mild | 7 Participants |
| PF-06700841 1.0% BID | Number of Participants With TEAEs by Severity | Severe | 2 Participants |
| PF-06700841 1.0% BID | Number of Participants With TEAEs by Severity | Mild | 11 Participants |
| PF-06700841 1.0% BID | Number of Participants With TEAEs by Severity | Moderate | 5 Participants |
| PF-06700841 3.0% BID | Number of Participants With TEAEs by Severity | Severe | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants With TEAEs by Severity | Mild | 6 Participants |
| PF-06700841 3.0% BID | Number of Participants With TEAEs by Severity | Moderate | 6 Participants |
Secondary
Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and all non-SAEs. Treatment emergent AEs (TEAEs) were events that occurred between first dose of study drug and up to 4 weeks after last dose that were absent before treatment or that worsened relative to pretreatment state. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. Relatedness to study drug was assessed by the investigator.
Time frame: Day 1 of study drug dose to maximum of 4 weeks post last dose (maximum up to 16 weeks)
Population: Safety analysis set (SAS) included participants who received at least 1 dose of investigational product.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Vehicle Once Daily (QD) | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent AEs | 17 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent SAEs | 1 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related AEs | 1 Participants |
| Vehicle Once Daily (QD) | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related SAEs | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related SAEs | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent AEs | 16 Participants |
| PF-06700841 0.1% QD | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent SAEs | 0 Participants |
| PF-06700841 0.1% QD | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related AEs | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent SAEs | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related SAEs | 0 Participants |
| PF-06700841 0.3% QD | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related AEs | 2 Participants |
| PF-06700841 0.3% QD | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent AEs | 14 Participants |
| PF-06700841 1.0% QD | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent AEs | 17 Participants |
| PF-06700841 1.0% QD | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent SAEs | 1 Participants |
| PF-06700841 1.0% QD | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related AEs | 2 Participants |
| PF-06700841 1.0% QD | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related SAEs | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related AEs | 3 Participants |
| PF-06700841 3.0% QD | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent SAEs | 0 Participants |
| PF-06700841 3.0% QD | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent AEs | 14 Participants |
| PF-06700841 3.0% QD | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related SAEs | 0 Participants |
| Pooled Vehicle BID | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related SAEs | 0 Participants |
| Pooled Vehicle BID | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent AEs | 20 Participants |
| Pooled Vehicle BID | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related AEs | 2 Participants |
| Pooled Vehicle BID | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent SAEs | 1 Participants |
| PF-06700841 0.3% BID | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related AEs | 3 Participants |
| PF-06700841 0.3% BID | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent SAEs | 1 Participants |
| PF-06700841 0.3% BID | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related SAEs | 0 Participants |
| PF-06700841 0.3% BID | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent AEs | 13 Participants |
| PF-06700841 1.0% BID | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent SAEs | 2 Participants |
| PF-06700841 1.0% BID | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related SAEs | 0 Participants |
| PF-06700841 1.0% BID | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related AEs | 3 Participants |
| PF-06700841 1.0% BID | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent AEs | 18 Participants |
| PF-06700841 3.0% BID | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent AEs | 12 Participants |
| PF-06700841 3.0% BID | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related SAEs | 0 Participants |
| PF-06700841 3.0% BID | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-related AEs | 1 Participants |
| PF-06700841 3.0% BID | Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs | Treatment-emergent SAEs | 0 Participants |
Secondary
Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16
PSI was a self-administered 8-item questionnaire that measured the severity of psoriasis symptoms over the past 24 hours and the past 7 days. PSI included following 8 items: itch, pain, burning, stinging, cracking, scaling, flaking, and redness. Each item was rated on a scale from 0 to 4, where 0= not at all severe, 1= mild, 2= moderate, 3= severe and 4= very severe. Scores from all items were summed to give PSI score range from 0 (no severity) to 32 (maximum severity), higher PSI score indicated greater severity.
Time frame: Week 1, 2, 4, 6, 8, 10, 12, 14, and 16
Population: EAS included all randomized participants who receive at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure and 'number analyzed' signifies number of participants evaluable at specified time points.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vehicle Once Daily (QD) | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 24.1 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 31.0 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 4 | 15.6 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 7.4 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 8.6 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 18.8 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 5.7 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 23.3 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 7.1 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 26.7 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 4 | 29.0 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 35.5 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 42.9 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 51.7 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 44.0 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 19.4 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 44.4 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 22.2 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 46.2 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 11.8 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 45.8 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 30.4 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 32.0 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 18.2 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 40.0 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 4 | 29.6 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 50.0 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 62.1 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 4 | 48.5 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 54.2 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 22.2 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 67.7 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 54.2 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 54.8 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 34.3 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 62.1 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 50.0 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 52.0 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 42.9 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 64.3 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 4 | 38.2 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 55.6 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 31.4 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 37.0 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 13.5 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 20.8 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 45.2 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 31.6 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 41.7 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 4 | 26.1 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 36.7 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 19.1 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 35.5 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 25.9 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 56.5 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 30.4 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 50.0 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 11.4 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 25.7 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 66.7 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 4 | 31.0 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 18.2 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 62.5 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 36.0 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 4 | 51.6 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 48.1 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 35.7 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 46.4 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 46.4 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 26.5 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 31.4 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 22.7 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 32.3 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 24.1 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 36.0 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 33.3 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 59.3 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 33.3 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 4 | 35.5 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 31.6 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 17.4 Percentage of participants |
Comparison: Week 2p-value: 0.063690% CI: [-1, 28.5]Chan and Zhang method
Comparison: Week 2p-value: 0.143590% CI: [-4.9, 24.5]Chan and Zhang method
Comparison: Week 1p-value: 0.054490% CI: [-0.3, 27.9]Chan and Zhang method
Comparison: Week 1p-value: 0.269790% CI: [-6.3, 19.6]Chan and Zhang method
Comparison: Week 1p-value: 0.028690% CI: [2, 31]Chan and Zhang method
Comparison: Week 1p-value: 0.151290% CI: [-4.7, 20.8]Chan and Zhang method
Comparison: Week 1p-value: 0.7990% CI: [-21.9, 7.4]Chan and Zhang method
Comparison: Week 1p-value: 0.313790% CI: [-8.5, 24]Chan and Zhang method
Comparison: Week 1p-value: 0.378990% CI: [-10.9, 22.6]Chan and Zhang method
Comparison: Week 2p-value: 0.005890% CI: [8.9, 42.4]Chan and Zhang method
Comparison: Week 2p-value: 0.011290% CI: [6.5, 38.9]Chan and Zhang method
Comparison: Week 2p-value: 0.334990% CI: [-10.8, 21.3]Chan and Zhang method
Comparison: Week 2p-value: 0.206590% CI: [-6.1, 27.7]Chan and Zhang method
Comparison: Week 2p-value: 0.187190% CI: [-5.6, 29.1]Chan and Zhang method
Comparison: Week 4p-value: 0.124590% CI: [-4.9, 31.4]Chan and Zhang method
Comparison: Week 4p-value: 0.12890% CI: [-4.7, 33.7]Chan and Zhang method
Comparison: Week 4p-value: 0.00390% CI: [12.4, 50.5]Chan and Zhang method
Comparison: Week 4p-value: 0.023590% CI: [3.1, 40.6]Chan and Zhang method
Comparison: Week 4p-value: 0.372890% CI: [-13.6, 24.1]Chan and Zhang method
Comparison: Week 4p-value: 0.015390% CI: [4, 43.6]Chan and Zhang method
Comparison: Week 4p-value: 0.254390% CI: [-8.8, 27.8]Chan and Zhang method
Comparison: Week 6p-value: 0.278590% CI: [-10.2, 26.4]Chan and Zhang method
Comparison: Week 6p-value: 0.143490% CI: [-7.4, 33.7]Chan and Zhang method
Comparison: Week 6p-value: 0.001590% CI: [12.8, 54.1]Chan and Zhang method
Comparison: Week 6p-value: 0.024290% CI: [3.4, 43.9]Chan and Zhang method
Comparison: Week 6p-value: 0.003790% CI: [10, 54.1]Chan and Zhang method
Comparison: Week 6p-value: 0.103790% CI: [-4.9, 36.7]Chan and Zhang method
Comparison: Week 6p-value: 0.460790% CI: [-17.7, 22.5]Chan and Zhang method
Comparison: Week 8p-value: 0.172590% CI: [-8, 31.9]Chan and Zhang method
Comparison: Week 8p-value: 0.045190% CI: [0.2, 43.6]Chan and Zhang method
Comparison: Week 8p-value: 0.000390% CI: [21.3, 62.9]Chan and Zhang method
Comparison: Week 8p-value: 0.023990% CI: [3.8, 47.6]Chan and Zhang method
Comparison: Week 8p-value: 0.064390% CI: [-2.1, 41.2]Chan and Zhang method
Comparison: Week 8p-value: 0.667690% CI: [-25.9, 15.9]Chan and Zhang method
Comparison: Week 8p-value: 0.089890% CI: [-4.2, 37.8]Chan and Zhang method
Comparison: Week 10p-value: 0.270790% CI: [-10.1, 32.9]Chan and Zhang method
Comparison: Week 10p-value: 0.298190% CI: [-14.2, 31]Chan and Zhang method
Comparison: Week 10p-value: 0.01190% CI: [8, 51.4]Chan and Zhang method
Comparison: Week 10p-value: 0.008390% CI: [9.1, 53.2]Chan and Zhang method
Comparison: Week 10p-value: 0.421790% CI: [-18.3, 27.5]Chan and Zhang method
Comparison: Week 10p-value: 0.515290% CI: [-20.8, 23.2]Chan and Zhang method
Comparison: Week 10p-value: 0.700290% CI: [-33.1, 11.7]Chan and Zhang method
Comparison: Week 12p-value: 0.016990% CI: [5.2, 47.9]Chan and Zhang method
Comparison: Week 12p-value: 0.028390% CI: [3.2, 46.2]Chan and Zhang method
Comparison: Week 12p-value: 0.00290% CI: [14.3, 57.1]Chan and Zhang method
Comparison: Week 12p-value: 0.009590% CI: [8.4, 51.5]Chan and Zhang method
Comparison: Week 12p-value: 0.079890% CI: [-2.7, 42.6]Chan and Zhang method
Comparison: Week 12p-value: 0.284890% CI: [-11.3, 31.8]Chan and Zhang method
Comparison: Week 12p-value: 0.506290% CI: [-21.1, 23.1]Chan and Zhang method
Comparison: Week 14p-value: 0.001290% CI: [16.7, 55.3]Chan and Zhang method
Comparison: Week 14p-value: 0.000790% CI: [17.3, 57.4]Chan and Zhang method
Comparison: Week 14p-value: 0.000190% CI: [24.6, 65.1]Chan and Zhang method
Comparison: Week 14p-value: 0.003990% CI: [9.5, 48.7]Chan and Zhang method
Comparison: Week 14p-value: 0.389590% CI: [-17.5, 26.5]Chan and Zhang method
Comparison: Week 14p-value: 0.279390% CI: [-11.8, 31.8]Chan and Zhang method
Comparison: Week 14p-value: 0.702790% CI: [-28.4, 12.2]Chan and Zhang method
Comparison: Week 16p-value: 0.000990% CI: [15.4, 55.2]Chan and Zhang method
Comparison: Week 16p-value: 0.020590% CI: [4.1, 43.2]Chan and Zhang method
Comparison: Week 16p-value: 0.000190% CI: [24.6, 65.7]Chan and Zhang method
Comparison: Week 16p-value: 0.000290% CI: [21.5, 62.9]Chan and Zhang method
Comparison: Week 16p-value: 0.920990% CI: [-38.3, 3.2]Chan and Zhang method
Comparison: Week 16p-value: 0.79390% CI: [-34.4, 8.7]Chan and Zhang method
Comparison: Week 16p-value: 0.615690% CI: [-28, 20.1]Chan and Zhang method
Secondary
Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16
The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14, and 16
Population: EAS included all randomized participants who receive at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure and 'number analyzed' signifies number of participants evaluable at specified time points.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vehicle Once Daily (QD) | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 10.3 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 3.1 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 3.4 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 3.1 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 3.4 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | week 4 | 3.1 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 10.3 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 3.2 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 6.7 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 3.3 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 6.7 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 7.7 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 0 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 3.0 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 11.1 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 0 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | week 4 | 0 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 10.3 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 7.7 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 8.0 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 7.4 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | week 4 | 3.6 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 0 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 0 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 17.4 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 8.7 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 7.4 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 0 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 2.9 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 21.4 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 17.2 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | week 4 | 0 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 6.5 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 20.7 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 6.5 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 25.0 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 14.3 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 0 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 0 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | week 4 | 0 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 10.3 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 14.3 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 17.9 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 14.3 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 15.4 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 0 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 13.9 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 10.3 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | week 4 | 8.9 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 13.9 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 20.6 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 18.2 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 2.2 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 16.1 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 13.0 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 0 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 16.0 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 10.7 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | week 4 | 6.7 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 20.8 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 12.5 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 0 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 13.0 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 10.7 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 6.3 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 20.0 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 13.8 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 12.5 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 10.7 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 2.9 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 24.1 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | week 4 | 3.0 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 8 | 14.3 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 10 | 15.4 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | week 4 | 12.1 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 12 | 17.9 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 2 | 5.7 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 14 | 14.8 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 1 | 2.7 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 16 | 15.4 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 | Week 6 | 10.3 Percentage of participants |
Comparison: Week 1p-value: 0.422590% CI: [-11.2, 10.4]Chan and Zhang method
Comparison: Week 1p-value: 0.748390% CI: [-14, 5]Chan and Zhang method
Comparison: Week 1p-value: 0.753990% CI: [-14, 4.8]Chan and Zhang method
Comparison: Week 1p-value: 0.753990% CI: [-14, 4.8]Chan and Zhang method
Comparison: Week 1p-value: 0.590% CI: [-6.4, 8.9]Chan and Zhang method
Comparison: Week 1p-value: 0.212590% CI: [-3.4, 13.2]Chan and Zhang method
Comparison: Week 1p-value: 0.226790% CI: [-3.5, 12.2]Chan and Zhang method
Comparison: Week 2p-value: 0.759290% CI: [-14, 4.6]Chan and Zhang method
Comparison: Week 2p-value: 0.729990% CI: [-14, 5.5]Chan and Zhang method
Comparison: Week 2p-value: 0.446390% CI: [-11.3, 9.4]Chan and Zhang method
Comparison: Week 2p-value: 0.753990% CI: [-14, 4.8]Chan and Zhang method
Comparison: Week 2p-value: 0.700990% CI: [-10.1, 5.9]Chan and Zhang method
Comparison: Week 2p-value: 0.250790% CI: [-4.5, 15.6]Chan and Zhang method
Comparison: Week 2p-value: 0.299390% CI: [-4.8, 14.3]Chan and Zhang method
Comparison: Week 4p-value: 0.736390% CI: [-14, 5.5]Chan and Zhang method
Comparison: Week 4p-value: 0.536990% CI: [-10.5, 12.3]Chan and Zhang method
Comparison: Week 4p-value: 0.748390% CI: [-14, 5]Chan and Zhang method
Comparison: Week 4p-value: 0.748390% CI: [-14, 5]Chan and Zhang method
Comparison: Week 4p-value: 0.59990% CI: [-13.7, 11.6]Chan and Zhang method
Comparison: Week 4p-value: 0.792690% CI: [-16.4, 4.9]Chan and Zhang method
Comparison: Week 4p-value: 0.340290% CI: [-9, 17.6]Chan and Zhang method
Comparison: Week 6p-value: 0.736490% CI: [-14.4, 5.7]Chan and Zhang method
Comparison: Week 6p-value: 0.300990% CI: [-7.4, 17.7]Chan and Zhang method
Comparison: Week 6p-value: 0.3490% CI: [-8.1, 15.9]Chan and Zhang method
Comparison: Week 6p-value: 0.163190% CI: [-4.8, 21.1]Chan and Zhang method
Comparison: Week 6p-value: 0.621490% CI: [-17.8, 13]Chan and Zhang method
Comparison: Week 6p-value: 0.621490% CI: [-17.8, 13]Chan and Zhang method
Comparison: Week 6p-value: 0.641390% CI: [-17.9, 11.7]Chan and Zhang method
Comparison: Week 8p-value: 0.590% CI: [-13.1, 13.1]Chan and Zhang method
Comparison: Week 8p-value: 0.513490% CI: [-12.6, 15.2]Chan and Zhang method
Comparison: Week 8p-value: 0.446890% CI: [-13.4, 12.5]Chan and Zhang method
Comparison: Week 8p-value: 0.277890% CI: [-6.8, 23.9]Chan and Zhang method
Comparison: Week 8p-value: 0.457190% CI: [-14.5, 21]Chan and Zhang method
Comparison: Week 8p-value: 0.474190% CI: [-15.3, 16.7]Chan and Zhang method
Comparison: Week 8p-value: 0.515390% CI: [-14.8, 16.7]Chan and Zhang method
Comparison: Week 10p-value: 0.828790% CI: [-21.1, 5.3]Chan and Zhang method
Comparison: Week 10p-value: 0.567590% CI: [-17.8, 14.2]Chan and Zhang method
Comparison: Week 10p-value: 0.264890% CI: [-9.8, 23.2]Chan and Zhang method
Comparison: Week 10p-value: 0.379290% CI: [-11.8, 20.8]Chan and Zhang method
Comparison: Week 10p-value: 0.443890% CI: [-16.3, 23.1]Chan and Zhang method
Comparison: Week 10p-value: 0.701490% CI: [-23.3, 9.4]Chan and Zhang method
Comparison: Week 10p-value: 0.584190% CI: [-19.7, 15]Chan and Zhang method
Comparison: Week 12p-value: 0.590% CI: [-15.3, 15.3]Chan and Zhang method
Comparison: Week 12p-value: 0.583490% CI: [-17.5, 12.3]Chan and Zhang method
Comparison: Week 12p-value: 0.153490% CI: [-6.4, 27.2]Chan and Zhang method
Comparison: Week 12p-value: 0.27290% CI: [-8.8, 24.9]Chan and Zhang method
Comparison: Week 12p-value: 0.681590% CI: [-25.1, 10.4]Chan and Zhang method
Comparison: Week 12p-value: 0.3990% CI: [-14.4, 22]Chan and Zhang method
Comparison: Week 12p-value: 0.586590% CI: [-20, 15.9]Chan and Zhang method
Comparison: Week 14p-value: 0.308790% CI: [-8.2, 18.9]Chan and Zhang method
Comparison: Week 14p-value: 0.313790% CI: [-8.2, 20.9]Chan and Zhang method
Comparison: Week 14p-value: 0.024590% CI: [2.7, 34.8]Chan and Zhang method
Comparison: Week 14p-value: 0.111990% CI: [-3, 26]Chan and Zhang method
Comparison: Week 14p-value: 0.41490% CI: [-13.2, 20.4]Chan and Zhang method
Comparison: Week 14p-value: 0.235690% CI: [-7.2, 28.5]Chan and Zhang method
Comparison: Week 14p-value: 0.363890% CI: [-11.5, 21.5]Chan and Zhang method
Comparison: Week 16p-value: 0.161390% CI: [-5.2, 22.9]Chan and Zhang method
Comparison: Week 16p-value: 0.055790% CI: [-0.5, 31.4]Chan and Zhang method
Comparison: Week 16p-value: 0.011490% CI: [5.6, 38.3]Chan and Zhang method
Comparison: Week 16p-value: 0.075390% CI: [-1.8, 28.1]Chan and Zhang method
Comparison: Week 16p-value: 0.563590% CI: [-20.1, 15.2]Chan and Zhang method
Comparison: Week 16p-value: 0.620190% CI: [-20.3, 14.5]Chan and Zhang method
Comparison: Week 16p-value: 0.479290% CI: [-17.6, 17]Chan and Zhang method
Secondary
Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16
PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category. Scale for PGA: 0= clear, 1= almost clear, 2= mild, 3= moderate and 4= severe. Higher scores indicate more severity.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10, 14, and 16
Population: EAS included all randomized participants who receive at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, number analyzed signifies the number of participants evaluable at specified time points.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Vehicle Once Daily (QD) | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 4 | 5.6 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 2 | 2.8 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 1 | 2.8 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 6 | 8.3 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 8 | 11.1 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 10 | 8.3 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 14 | 2.8 Percentage of participants |
| Vehicle Once Daily (QD) | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 16 | 5.6 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 6 | 5.4 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 2 | 0 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 14 | 13.5 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 4 | 5.4 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 10 | 5.4 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 1 | 2.7 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 16 | 11.4 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 8 | 5.4 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 16 | 8.6 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 6 | 2.7 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 10 | 8.1 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 2 | 0 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 14 | 5.6 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 4 | 0 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 1 | 2.7 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 8 | 5.4 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 2 | 2.8 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 14 | 8.6 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 16 | 14.3 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 4 | 5.6 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 6 | 8.3 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 8 | 2.8 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 1 | 0 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 10 | 8.3 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 8 | 10.8 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 6 | 13.5 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 16 | 16.2 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 10 | 16.2 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 2 | 2.7 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 14 | 13.5 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 4 | 5.4 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 1 | 0 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 2 | 2.0 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 16 | 8.2 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 4 | 8.2 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 14 | 6.3 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 8 | 6.1 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 6 | 8.2 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 10 | 16.3 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 1 | 0 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 16 | 14.7 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 1 | 0 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 4 | 8.3 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 10 | 16.7 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 8 | 13.9 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 6 | 8.3 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 2 | 0 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 14 | 8.8 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 1 | 5.7 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 2 | 5.7 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 4 | 11.4 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 6 | 5.7 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 8 | 5.7 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 10 | 8.6 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 16 | 11.8 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 14 | 11.8 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 16 | 16.2 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 14 | 8.1 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 10 | 13.2 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 8 | 18.4 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 6 | 13.2 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 4 | 21.1 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 2 | 10.5 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 | Week 1 | 5.3 Percentage of participants |
Comparison: Week 1p-value: 0.421690% CI: [-9.4, 9.1]Chan and Zhang method
Comparison: Week 1p-value: 0.421690% CI: [-9.4, 9.1]Chan and Zhang method
Comparison: Week 1p-value: 0.736290% CI: [-12.5, 5]Chan and Zhang method
Comparison: Week 1p-value: 0.741790% CI: [-12.5, 4.7]Chan and Zhang method
Comparison: Week 1p-value: 0.590% CI: [-5.9, 8]Chan and Zhang method
Comparison: Week 1p-value: 0.071490% CI: [-0.8, 16.9]Chan and Zhang method
Comparison: Week 1p-value: 0.081390% CI: [-1.1, 15.7]Chan and Zhang method
Comparison: Week 2p-value: 0.741790% CI: [-12.5, 4.7]Chan and Zhang method
Comparison: Week 2p-value: 0.741790% CI: [-12.5, 4.7]Chan and Zhang method
Comparison: Week 2p-value: 0.590% CI: [-9.6, 9.6]Chan and Zhang method
Comparison: Week 2p-value: 0.421690% CI: [-9.4, 9.1]Chan and Zhang method
Comparison: Week 2p-value: 0.689490% CI: [-9.4, 5.9]Chan and Zhang method
Comparison: Week 2p-value: 0.251890% CI: [-4.2, 14.3]Chan and Zhang method
Comparison: Week 2p-value: 0.056590% CI: [-0.3, 20.3]Chan and Zhang method
Comparison: Week 4p-value: 0.444690% CI: [-11, 11]Chan and Zhang method
Comparison: Week 4p-value: 0.900190% CI: [-16.5, 1.9]Chan and Zhang method
Comparison: Week 4p-value: 0.590% CI: [-11, 11]Chan and Zhang method
Comparison: Week 4p-value: 0.444690% CI: [-11, 11]Chan and Zhang method
Comparison: Week 4p-value: 0.505490% CI: [-10.5, 12.5]Chan and Zhang method
Comparison: Week 4p-value: 0.340190% CI: [-8.2, 16.9]Chan and Zhang method
Comparison: Week 4p-value: 0.048990% CI: [0.1, 27.5]Chan and Zhang method
Comparison: Week 6p-value: 0.634990% CI: [-14.8, 8.4]Chan and Zhang method
Comparison: Week 6p-value: 0.825390% CI: [-17.2, 4.4]Chan and Zhang method
Comparison: Week 6p-value: 0.590% CI: [-12.5, 12.5]Chan and Zhang method
Comparison: Week 6p-value: 0.270990% CI: [-8.3, 19.1]Chan and Zhang method
Comparison: Week 6p-value: 0.505490% CI: [-10.5, 12.5]Chan and Zhang method
Comparison: Week 6p-value: 0.631990% CI: [-12.9, 9.3]Chan and Zhang method
Comparison: Week 6p-value: 0.319990% CI: [-6.4, 18.1]Chan and Zhang method
Comparison: Week 8p-value: 0.730690% CI: [-19.1, 6.1]Chan and Zhang method
Comparison: Week 8p-value: 0.730690% CI: [-19.1, 6.1]Chan and Zhang method
Comparison: Week 8p-value: 0.880890% CI: [-20.6, 2.7]Chan and Zhang method
Comparison: Week 8p-value: 0.464490% CI: [-13.7, 13.7]Chan and Zhang method
Comparison: Week 8p-value: 0.153490% CI: [-3.4, 20.9]Chan and Zhang method
Comparison: Week 8p-value: 0.486790% CI: [-10, 11.4]Chan and Zhang method
Comparison: Week 8p-value: 0.043590% CI: [0.4, 25.9]Chan and Zhang method
Comparison: Week 10p-value: 0.634990% CI: [-14.8, 8.4]Chan and Zhang method
Comparison: Week 10p-value: 0.456590% CI: [-12.6, 12.5]Chan and Zhang method
Comparison: Week 10p-value: 0.590% CI: [-12.5, 12.5]Chan and Zhang method
Comparison: Week 10p-value: 0.176590% CI: [-5.7, 21.8]Chan and Zhang method
Comparison: Week 10p-value: 0.501390% CI: [-14, 15.2]Chan and Zhang method
Comparison: Week 10p-value: 0.796990% CI: [-20.7, 5.9]Chan and Zhang method
Comparison: Week 10p-value: 0.642490% CI: [-16.4, 10.6]Chan and Zhang method
Comparison: Week 14p-value: 0.06290% CI: [-0.7, 23.6]Chan and Zhang method
Comparison: Week 14p-value: 0.340290% CI: [-7, 13.4]Chan and Zhang method
Comparison: Week 14p-value: 0.174390% CI: [-4.5, 17.6]Chan and Zhang method
Comparison: Week 14p-value: 0.06290% CI: [-0.7, 23.6]Chan and Zhang method
Comparison: Week 14p-value: 0.353490% CI: [-7.8, 15.4]Chan and Zhang method
Comparison: Week 14p-value: 0.250890% CI: [-5.5, 18.8]Chan and Zhang method
Comparison: Week 14p-value: 0.423890% CI: [-8.2, 13.6]Chan and Zhang method
Comparison: Week 16p-value: 0.269690% CI: [-6.2, 19.3]Chan and Zhang method
Comparison: Week 16p-value: 0.364890% CI: [-8.6, 15.3]Chan and Zhang method
Comparison: Week 16p-value: 0.126790% CI: [-3.8, 22.2]Chan and Zhang method
Comparison: Week 16p-value: 0.083290% CI: [-2.5, 24.4]Chan and Zhang method
Comparison: Week 16p-value: 0.209990% CI: [-5.7, 21.3]Chan and Zhang method
Comparison: Week 16p-value: 0.347490% CI: [-8, 17.4]Chan and Zhang method
Comparison: Week 16p-value: 0.212490% CI: [-4, 21.6]Chan and Zhang method
Secondary
Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12
PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category. Scale for PGA: 0= clear, 1= almost clear, 2= mild, 3= moderate and 4= severe. Higher scores indicate more severity.
Time frame: Baseline, Week 12
Population: EAS included all randomized participants who receive at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Vehicle Once Daily (QD) | Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12 | 6.9 Percentage of participants |
| PF-06700841 0.1% QD | Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12 | 10.3 Percentage of participants |
| PF-06700841 0.3% QD | Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12 | 15.4 Percentage of participants |
| PF-06700841 1.0% QD | Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12 | 10.3 Percentage of participants |
| PF-06700841 3.0% QD | Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12 | 21.4 Percentage of participants |
| Pooled Vehicle BID | Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12 | 14.7 Percentage of participants |
| PF-06700841 0.3% BID | Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12 | 20.8 Percentage of participants |
| PF-06700841 1.0% BID | Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12 | 27.6 Percentage of participants |
| PF-06700841 3.0% BID | Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12 | 17.9 Percentage of participants |
p-value: 0.374790% CI: [-10.6, 17.9]Chan and Zhang method
p-value: 0.24390% CI: [-6.6, 25.9]Chan and Zhang method
p-value: 0.374790% CI: [-10.6, 17.9]Chan and Zhang method
p-value: 0.06650.0665% CI: [-1.3, 31.5]Chan and Zhang method
p-value: 0.342390% CI: [-12.1, 25.5]Chan and Zhang method
p-value: 0.127190% CI: [-4.7, 30.9]Chan and Zhang method
p-value: 0.40190% CI: [-13.2, 21.1]Chan and Zhang method
Secondary
Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12
The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
Time frame: Baseline, Week 1, 2, 4, 6, 8, 10 and 12
Population: EAS included all randomized participants who receive at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, 'overall number of participants analyzed' signifies number of participants evaluable for this outcome measure and 'number analyzed' signifies number of participants evaluable at specified time points.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Vehicle Once Daily (QD) | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -25.3 Percent change | Standard Error 6.48 |
| Vehicle Once Daily (QD) | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -20.0 Percent change | Standard Error 7.36 |
| Vehicle Once Daily (QD) | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -21.6 Percent change | Standard Error 4.25 |
| Vehicle Once Daily (QD) | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -15.5 Percent change | Standard Error 3.62 |
| Vehicle Once Daily (QD) | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -23.7 Percent change | Standard Error 5.88 |
| Vehicle Once Daily (QD) | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -24.1 Percent change | Standard Error 4.69 |
| Vehicle Once Daily (QD) | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -26.8 Percent change | Standard Error 6.42 |
| PF-06700841 0.1% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -20.3 Percent change | Standard Error 5.83 |
| PF-06700841 0.1% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -12.9 Percent change | Standard Error 3.57 |
| PF-06700841 0.1% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -29.1 Percent change | Standard Error 7.3 |
| PF-06700841 0.1% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -12.4 Percent change | Standard Error 4.1 |
| PF-06700841 0.1% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -27.6 Percent change | Standard Error 6.34 |
| PF-06700841 0.1% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -20.5 Percent change | Standard Error 4.65 |
| PF-06700841 0.1% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -25.6 Percent change | Standard Error 6.44 |
| PF-06700841 0.3% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -18.5 Percent change | Standard Error 7.7 |
| PF-06700841 0.3% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -22.9 Percent change | Standard Error 6.73 |
| PF-06700841 0.3% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -18.4 Percent change | Standard Error 6.18 |
| PF-06700841 0.3% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -14.3 Percent change | Standard Error 6.78 |
| PF-06700841 0.3% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -12.6 Percent change | Standard Error 4.34 |
| PF-06700841 0.3% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -15.6 Percent change | Standard Error 4.9 |
| PF-06700841 0.3% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -8.2 Percent change | Standard Error 3.56 |
| PF-06700841 1.0% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -17.6 Percent change | Standard Error 4.59 |
| PF-06700841 1.0% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -33.7 Percent change | Standard Error 7.3 |
| PF-06700841 1.0% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -21.8 Percent change | Standard Error 5.83 |
| PF-06700841 1.0% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -35.3 Percent change | Standard Error 6.36 |
| PF-06700841 1.0% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -10.4 Percent change | Standard Error 3.49 |
| PF-06700841 1.0% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -30.5 Percent change | Standard Error 6.41 |
| PF-06700841 1.0% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -17.9 Percent change | Standard Error 4.13 |
| PF-06700841 3.0% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -36.0 Percent change | Standard Error 5.92 |
| PF-06700841 3.0% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -13.0 Percent change | Standard Error 3.51 |
| PF-06700841 3.0% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -19.8 Percent change | Standard Error 4.14 |
| PF-06700841 3.0% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -25.1 Percent change | Standard Error 4.61 |
| PF-06700841 3.0% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -35.9 Percent change | Standard Error 6.57 |
| PF-06700841 3.0% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -36.1 Percent change | Standard Error 6.48 |
| PF-06700841 3.0% QD | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -39.0 Percent change | Standard Error 7.47 |
| Pooled Vehicle BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -13.2 Percent change | Standard Error 5.69 |
| Pooled Vehicle BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -12.5 Percent change | Standard Error 7.62 |
| Pooled Vehicle BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -7.4 Percent change | Standard Error 3.1 |
| Pooled Vehicle BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -18.1 Percent change | Standard Error 6.7 |
| Pooled Vehicle BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -17.8 Percent change | Standard Error 6.1 |
| Pooled Vehicle BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -9.6 Percent change | Standard Error 8.61 |
| Pooled Vehicle BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -11.7 Percent change | Standard Error 3.99 |
| PF-06700841 0.3% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -35.2 Percent change | Standard Error 8.07 |
| PF-06700841 0.3% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -36.6 Percent change | Standard Error 7.31 |
| PF-06700841 0.3% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -33.4 Percent change | Standard Error 9.12 |
| PF-06700841 0.3% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -34.1 Percent change | Standard Error 10.35 |
| PF-06700841 0.3% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -33.9 Percent change | Standard Error 6.85 |
| PF-06700841 0.3% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -9.0 Percent change | Standard Error 3.64 |
| PF-06700841 0.3% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -20.7 Percent change | Standard Error 4.6 |
| PF-06700841 1.0% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -31.2 Percent change | Standard Error 7.12 |
| PF-06700841 1.0% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -24.1 Percent change | Standard Error 6.66 |
| PF-06700841 1.0% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -32.4 Percent change | Standard Error 7.76 |
| PF-06700841 1.0% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -23.3 Percent change | Standard Error 4.68 |
| PF-06700841 1.0% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -35.7 Percent change | Standard Error 9.84 |
| PF-06700841 1.0% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -35.1 Percent change | Standard Error 8.75 |
| PF-06700841 1.0% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -13.7 Percent change | Standard Error 3.58 |
| PF-06700841 3.0% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 1 | -13.5 Percent change | Standard Error 3.52 |
| PF-06700841 3.0% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 10 | -34.6 Percent change | Standard Error 8.77 |
| PF-06700841 3.0% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 12 | -33.7 Percent change | Standard Error 9.88 |
| PF-06700841 3.0% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 2 | -24.7 Percent change | Standard Error 4.58 |
| PF-06700841 3.0% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 8 | -34.3 Percent change | Standard Error 7.76 |
| PF-06700841 3.0% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 4 | -29.2 Percent change | Standard Error 6.64 |
| PF-06700841 3.0% BID | Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 | Change at Week 6 | -27.5 Percent change | Standard Error 7.08 |
Comparison: Week 1: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.691790% CI: [-5.86, 10.97]MMRM
Comparison: Week 1: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.924190% CI: [-1.09, 15.69]MMRM
Comparison: Week 1: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.844390% CI: [-3.21, 13.42]MMRM
Comparison: Week 1: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.691190% CI: [-5.82, 10.86]MMRM
Comparison: Week 1: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.367690% CI: [-9.56, 6.31]MMRM
Comparison: Week 1: Week 1: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.091590% CI: [-14.13, 1.5]MMRM
Comparison: Week 1: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.09790% CI: [-13.96, 1.65]MMRM
Comparison: Week 2: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.938990% CI: [-0.59, 18.97]MMRM
Comparison: Week 2: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errorsp-value: 0.929590% CI: [-1.06, 19.02]MMRM
Comparison: Week 2: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.730890% CI: [-6.15, 13.45]MMRM
Comparison: Week 2: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.619990% CI: [-8.01, 11.64]MMRM
Comparison: Week 2: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.069990% CI: [-19.13, 1.04]MMRM
Comparison: Week 2: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.0390% CI: [-21.79, -1.48]MMRM
Comparison: Week 2: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.016890% CI: [-23.15, -2.98]MMRM
Comparison: Week 4: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.708390% CI: [-7.3, 14.57]MMRM
Comparison: Week 4: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.895590% CI: [-2.66, 19.75]MMRM
Comparison: Week 4: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.838690% CI: [-4.35, 17.37]MMRM
Comparison: Week 4: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.437190% CI: [-11.93, 9.84]MMRM
Comparison: Week 4: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.010890% CI: [-35.42, -5.92]MMRM
Comparison: Week 4: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.106690% CI: [-25.43, 3.55]MMRM
Comparison: Week 4: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.034490% CI: [-30.54, -1.55]MMRM
Comparison: Week 6: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.659490% CI: [-10.3, 17.13]MMRM
Comparison: Week 6: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.730790% CI: [-8.85, 19.36]MMRM
Comparison: Week 6: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.591490% CI: [-11.78, 15.61]MMRM
Comparison: Week 6: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.070990% CI: [-26.13, 1.49]MMRM
Comparison: Week 6: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.025390% CI: [-34.55, -3.01]MMRM
Comparison: Week 6: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.07890% CI: [-28.89, 2.15]MMRM
Comparison: Week 6: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.151690% CI: [-25.17, 5.83]MMRM
Comparison: Week 8: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.486190% CI: [-15.45, 14.81]MMRM
Comparison: Week 8: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.879590% CI: [-4.48, 26.55]MMRM
Comparison: Week 8: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.286790% CI: [-20.22, 9.94]MMRM
Comparison: Week 8: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.126790% CI: [-25.86, 4.69]MMRM
Comparison: Week 8: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.052690% CI: [-34.48, 0.26]MMRM
Comparison: Week 8: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.082790% CI: [-31.26, 2.68]MMRM
Comparison: Week 8: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.059290% CI: [-33.12, 0.86]MMRM
Comparison: Week 10: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.465790% CI: [-15.72, 14.16]MMRM
Comparison: Week 10: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.661290% CI: [-11.52, 19.26]MMRM
Comparison: Week 10: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.174990% CI: [-23.42, 6.48]MMRM
Comparison: Week 10: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.154890% CI: [-24.39, 5.8]MMRM
Comparison: Week 10: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.0490% CI: [-40.67, -1.28]MMRM
Comparison: Week 10: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.026790% CI: [-41.82, -3.39]MMRM
Comparison: Week 10: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.029590% CI: [-41.42, -2.89]MMRM
Comparison: Week 12: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.190390% CI: [-26.3, 8.05]MMRM
Comparison: Week 12: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.55390% CI: [-16.21, 19.06]MMRM
Comparison: Week 12: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.093390% CI: [-30.92, 3.4]MMRM
Comparison: Week 12: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.03690% CI: [-36.37, -1.65]MMRM
Comparison: Week 12: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.035490% CI: [-46.85, -2.23]MMRM
Comparison: Week 12: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.023990% CI: [-47.77, -4.46]MMRM
Comparison: Week 12: MMRM analysis contains treatment, visit, and treatment by visit interaction as fixed factors; and baseline value as a covariate. Unstructured covariance matrix was used for model errors.p-value: 0.034290% CI: [-45.84, -2.38]MMRM
Secondary
Percent Change From Baseline in PASI Scores at Week 14 and 16
The PASI score (0-72, with higher score representing greater severity) is a measurement of the severity and extent of psoriasis. The four regions of the body parts are head (10%), arms (20%), trunk (30%) and legs (40%). In each region, the area is expressed as a score of 0 (nothing), 1 (1-9%), 2 (10-29%), 3 (30-49%), 4 (50-69%), 5 (70-89%) or 6 (90-100%). Within each area, the degree of severity for erythema, induration and scaling are estimated between 0 and 4, with 4 being the highest severity. The final score combines disease severity and effected BSA from for four regions using the formula PASI =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) + 0.3At(Et + It + St) + 0.4Al(El + Il + Sl) where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; l = lower limbs.
Time frame: Baseline, Week 14 and 16
Population: EAS included all randomized participants who receive at least 1 dose of investigational product (PF-06700841 or placebo) and Week 12 visits were not missing due to COVID-19 pandemic. Here, number analyzed signifies the number of participants evaluable at specified time points.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Vehicle Once Daily (QD) | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 6.12 Percent change | Standard Deviation 2.87 |
| Vehicle Once Daily (QD) | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -4.72 Percent change | Standard Deviation 56.401 |
| Vehicle Once Daily (QD) | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -12.76 Percent change | Standard Deviation 49.66 |
| PF-06700841 0.1% QD | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -23.01 Percent change | Standard Deviation 44.766 |
| PF-06700841 0.1% QD | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -25.94 Percent change | Standard Deviation 40.339 |
| PF-06700841 0.1% QD | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 7.19 Percent change | Standard Deviation 3.37 |
| PF-06700841 0.3% QD | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -8.58 Percent change | Standard Deviation 59.407 |
| PF-06700841 0.3% QD | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 6.46 Percent change | Standard Deviation 2.932 |
| PF-06700841 0.3% QD | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -9.00 Percent change | Standard Deviation 60.088 |
| PF-06700841 1.0% QD | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -29.24 Percent change | Standard Deviation 52.608 |
| PF-06700841 1.0% QD | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 6.63 Percent change | Standard Deviation 3.468 |
| PF-06700841 1.0% QD | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -23.14 Percent change | Standard Deviation 47.501 |
| PF-06700841 3.0% QD | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -30.07 Percent change | Standard Deviation 40.222 |
| PF-06700841 3.0% QD | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 6.83 Percent change | Standard Deviation 3.137 |
| PF-06700841 3.0% QD | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -27.17 Percent change | Standard Deviation 41.153 |
| Pooled Vehicle BID | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -5.74 Percent change | Standard Deviation 74.846 |
| Pooled Vehicle BID | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 6.08 Percent change | Standard Deviation 2.558 |
| Pooled Vehicle BID | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -3.75 Percent change | Standard Deviation 83.415 |
| PF-06700841 0.3% BID | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -9.99 Percent change | Standard Deviation 60.306 |
| PF-06700841 0.3% BID | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 7.07 Percent change | Standard Deviation 3.579 |
| PF-06700841 0.3% BID | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -14.18 Percent change | Standard Deviation 58.599 |
| PF-06700841 1.0% BID | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -27.56 Percent change | Standard Deviation 45.37 |
| PF-06700841 1.0% BID | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -24.09 Percent change | Standard Deviation 48.685 |
| PF-06700841 1.0% BID | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 5.80 Percent change | Standard Deviation 2.765 |
| PF-06700841 3.0% BID | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 14 | -19.74 Percent change | Standard Deviation 49.727 |
| PF-06700841 3.0% BID | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Change at Week 16 | -21.12 Percent change | Standard Deviation 52.521 |
| PF-06700841 3.0% BID | Percent Change From Baseline in PASI Scores at Week 14 and 16 | Baseline | 7.94 Percent change | Standard Deviation 4.071 |